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Abstract
Functional Domains of P450 1A1 and 1A2: Molecular Modeling-Guided
Structure-Function Study
Youbin Tu
Cytochromes P450 are a large family of heme-thiolate enzymes which
metabolize a wide variety of both endogenous and xenobiotic compounds. Human
P450 1A1 and 1A2 are two major members of the P450 1A subfamily. They share
72% sequence identity but display different specificities towards various substrates.
In order to further understand the structure-function relationships of these enzymes,
we have performed several molecular modeling-based studies that examined various
functional domains of P450 1As.
In the first part of this project, we have investigated the ligand binding domain
by developing a specificity prediction model based on the correlations between MD
(Molecular Dynamics)-based descriptors and the specificity towards resorufin
substrates of P450 1A2 WT and its five single mutants. The application of this
method to multiple mutants of P450 1A2 containing mutations at two to five of these
five key positions have led to the prediction that seven out of twenty six mutants
would shift specificity from P450 1A2 to 1A1. The results have been verified by site
directed mutagenesis and functional analysis of the mutant P450 enzymes.
Subsequently, molecular modeling methods were applied for P450-CPR
(Cytochrome P450 Reductase) docking, which helped to identify the key residues at
the reductase binding sites of P450 1A1 and 1A2. The effect of the substitution of
Asn-145 of P450 1A2 to Lys on substrate specificity and reductase binding have been
evaluated using site-directed mutagenesis and kinetics assays. Finally, we conducted
a preliminary study into the membrane anchoring domain by submerging P450 1A2
into the explicit membrane in two different orientations. Energy minimization and
short molecular dynamics simulations have been performed to make it ready for the
subsequent rigorous molecular dynamics simulations, which are expected to provide
the plausible membrane association model for P450 1A2.
For the majority of the modeling studies, we applied the first generation homology
models of P450 1As as the starting line. We also developed a second generation
homology models of P450 1A1 and 1A2 using a new strategy to optimize the active
site using ligand-enzyme interaction information. These models were based on the
structures of multiple eukaryotic P450s and NMR-derived T1 relaxation data using
phenacetin and acetaminophen as substrates.
Taken together, various molecular modeling techniques have been successfully
employed to study several functional domains of P450 1As. They helped to
investigate the structural basis of the enzyme function and gave insight into their
mechanism of action.

Acknowledgements
First of all, I would like to thank my advisor Dr. Grazyna D. Szklarz, who
shepherded me into the beautiful world of molecular modeling as early as 2002. Her
wisdom, insight and dedicated spirits in sciences have always impressed me very
much, and encouraged me to keep moving forward, although there is still a long way
to go for my academic career.
I would also like to give my special thanks to my current committee members.
Dr. Patrick S. Callery likes to enlighten me using instructive stories. I have to admit
sometimes it is pretty hard to figure out the implications, but once I understand them,
I really enjoy it! I would also like to thank him for his insightful guidance of my
research and future orientation for my career. Dr. Peter M. Gannett taught me
modeling techniques and continuously provided support for computation and
hardware resources. His broad knowledge in a wide range of interdisciplinary fields
really impressed me very much. Dr. Eugene Demchuk is always willing to talk with
me and shared his opinions on my projects and gave me great ideas from the
viewpoint of a biophysicist. Dr. Joseph K.H. Ma, who kindly joined my committee
in the last semester, gave me many suggestions and help for the preparation of my
dissertation. Moreover, I would like to thank my former committee member, Dr.
Robert L. Haining, who gave me a lot of guidance and help when I had difficulties
with molecular cloning and the interpretation of enzyme kinetics data.
Many thanks should also be given to my former colleagues: Jianguo Liu, Dr.
Rahul Deshmukh and Dr. Meena Sivaneri. They made a lot of contributions to our
previous work, most of which became the foundation for my current study.
Especially I would like to thank Dr. Spencer S. Ericksen, an insightful, energetic
young scientist in molecular modeling field. He is a very nice person and always
willing to help me when I have problems. We had extensive discussions and
cooperated on many projects I have been involved with. His fabulous ideas really
inspired me a lot.
Most importantly I would like to thank my dear wife, Jing Wang, who helped me
survive the last few years of my PhD career. She is always ready to support, comfort
me and give me love whenever I feel depressed. Without her love, I would not have
been able to finish my dissertation.
Finally, this dissertation should also be dedicated my grandmother, my farther
Liangming Tu and my mother Gengsheng Yang, who have continuously given me
great love and support since the beginning of my life. Although they may not quite
understand what I have done or could no longer stay around with me, their love will
always encourage me and never make me feel alone!

iii

Table of Contents
Abstract ............................................................................................................................................ ii
Acknowledgements..........................................................................................................................iii
Table of Contents .............................................................................................................................iv
List of Figures ..................................................................................................................................vi
List of Tables.................................................................................................................................. vii
Chapter 1...........................................................................................................................................1
Structure-function relationship of cytochromes P450.......................................................................1
1.1. Cytochromes P450 .............................................................................................................2
1.2. Cytochrome P450 Structure ...............................................................................................3
1.2.1. Bacterial Cytochromes P450...................................................................................3
1.2.2. Eukaryotic Cytochromes P450................................................................................4
1.2.3. The P450 Fold .........................................................................................................4
1.3. Catalytic Mechanism of Cytochromes P450......................................................................6
1.3.1. P450 Catalytic Cycle and the Intermediate Active Species (Cpd I) ........................6
1.3.2. Rate Limiting Steps.................................................................................................8
1.4. Functional Domains of Eukaryotic Microsomal P450s ...................................................11
1.4.1. Ligand Binding Domain........................................................................................11
1.4.2. CPR Binding Domain ...........................................................................................13
1.4.3. Membrane Anchoring Domain..............................................................................15
1.5. Molecular Modeling Methods Used to Study P450 Structure-Function Relationships....16
1.5.1 Overview of Molecular Modeling Methods Applied in Studies on P450 StructureFunction Relationships....................................................................................................16
1.5.2. Homology modeling..............................................................................................17
1.5.3. Molecular Mechanics ............................................................................................18
1.5.4 Molecular Dynamics ..............................................................................................18
1.5.5. Ligand-Protein Docking........................................................................................18
1.5.6. Protein-Protein Docking........................................................................................19
1.5.7. Other Methods.......................................................................................................20
1.5.8 Summary ................................................................................................................20
1.6. Cytochromes P450 1A1 and 1A2 – Previous Studies ......................................................20
1.7. Research Objectives and Overview of the Chapters ........................................................22
References...............................................................................................................................24
Chapter 2.........................................................................................................................................31
The Application of Molecular Modeling for Prediction of Substrate Specificity in Cytochrome
P450 1A2 Mutants ..........................................................................................................................31
Abstract ...................................................................................................................................32
Introduction.............................................................................................................................33
Methods and Materials............................................................................................................35
Results.....................................................................................................................................44
Discussion ...............................................................................................................................65
Conclusions and Future Directions .........................................................................................69

iv

Chapter 3.........................................................................................................................................73
Multiple Templates-based Homology Modeling of Human P450 1As Using T1 NMR Restraints for
the Refinement of the Active Sites..................................................................................................73
Abstract ...................................................................................................................................74
Introduction.............................................................................................................................75
Materials and Methods............................................................................................................78
Results and Discussion............................................................................................................88
Conclusions and Future Directions .......................................................................................100
References.............................................................................................................................101
Chapter 4.......................................................................................................................................105
Asn-145→Lys Substitution in Human Cytochrome P450 1A2 Decreases Reductase Binding ....105
Abstract .................................................................................................................................106
Introduction...........................................................................................................................107
Materials and Methods..........................................................................................................109
Results and Discussion.......................................................................................................... 111
Conclusions and Future Directions .......................................................................................125
References.............................................................................................................................126
Chapter 5.......................................................................................................................................129
Large Scale MD Simulations of P450 1A2 in Explicit Membrane: Comparison of Two Possible
Anchoring Orientations.................................................................................................................129
Abstract .................................................................................................................................130
Introduction...........................................................................................................................131
Modeling Methods ................................................................................................................132
Preliminary Results and Discussion......................................................................................133
Conclusions and Future Directions .......................................................................................134
References.............................................................................................................................138
Chapter 6.......................................................................................................................................140
Summary and Conclusions............................................................................................................140

v

List of Figures
Figure 1.1. Typical 3D structures of bacterial and eukaryotic P450s .........................5
Figure 1.2. The catalytic cycle of cytochrome P450 ..................................................7
Figure 1.3. The “oxygen rebound” mechanism of cytochrome P-450 catalyzed
hydroxylations...........................................................................................9
Figure 1.4. Active site of P450 1A2 .........................................................................12
Figure 2. 1. A scheme for MD-based scoring of productive binding orientations with
7-ethoxyresorufin....................................................................................41
Figure 2. 2. The active site of P450 1A2. .................................................................45
Figure 2.3. Experimental and predicted specificity for P450 1A2 WT and five single
mutants....................................................................................................52
Figure 2.4. The schematic tree structure of possible combinations of mutations
containing a L382V substitution.............................................................53
Figure 2.5. Experimental and predicted specificity for the selected multiple mutants
of P450 1A2. The specificity was expressed as EROD/MROD ratio.
The linear regression model used to calculate predicted specificity was
based on criterion P (r ≤ 3.0 Å)...............................................................60
Figure 3.1. Multiple sequence alignment of P450 1A1 with various prokaryotic and
eukaryotic P450s.....................................................................................80
Figure 3.2. Schematic diagram for the selection of templates..................................85
Figure 3.3. NMR T1 distance restraints used in Modeller.........................................86
Figure 3.4. Ramachandran plots for two generations of homology models of P450
1As. .........................................................................................................92
Figure 3.5. Comparison of the distribution of structural divergence between the new
and old homology models of P450 1A1/1A2. ........................................93
Figure 3.6. The distribution of structural conservation and divergence between the
new homology models of P450 1A1 and 1A2. .......................................94
Figure 3.7. Comparison of the new homology model of P450 1A2 with the 1A2
crystal structure.......................................................................................96
Figure 3. 8. Models of phenacetin (yellow) and acetaminophen (green) bound in the
second generation of homology models of P450 1A1 and 1A2. ............99
Figure 4.1.

Rate of NADPH consumption by P450 1A2 wild type, three mutants and
1A2 wild type as a function of the ratio of CPR vs. P450. ...................118
Figure 4.2. Comparison of the interactions between P450 1A2 and CPR regarding
the mutation N145K..............................................................................122
Figure 5.1. The solvent-accessible surface of P450 1A2 and 2B4..............................135
Figure 5.2. P450 1A2 in a fully hydrated membrane. ....................................................136
Figure 5.3. Two association orientations of P450 1A2 within POPC membrane ....137

vi

List of Tables

Table 2 1. Geometric analysis of the molecular dynamics results for the wild type
and five single mutants of P450 1A2. .............................................................50
Table 2.2. In silico E/M scores for the P450 1A2 multiple mutants predicted to
display large shifts in specificity. .....................................................................55
Table 2.3. Alkoxyresorufin O-dealkylase activities of P450 1A2 WT, the L382V
mutant and multiple1A2 mutants predicted to display large shifts in
specificity. .............................................................................................................58
Table 2.4. Predicted EROD/MROD ratios and their experimental values for the
P450 1A2 multiple mutants predicted to display large shifts in specificity.
.................................................................................................................................59

Table 2.5.

The comparison of the crystal structure of P450 1A2 with the homology
model. ....................................................................................................................61
Table 2.6. Geometric analysis of the molecular dynamics results for the wild type
P450 1A2 using either the homology model or the crystal structure .......64
Table 3.1. List of the crystal structures of eukaryotic P450s used as the templates ..81
Table 3.2. The comparison of the crystal structure of P450 1A2 with the 2nd
generation homology model. ............................................................................97
Table 4.1. Surface residues of P450 1A2 which may have potential electrostatic or
hydrophobic interactions with the residues of CPR...................................113
Table 4.2. Alkoxyresorufin O-dealkylase activities of P450 1A2 WT and mutants,
and P450 1A1 WT. ............................................................................................115
Table 4.3. Dissociation constants (KD) for binding of CPR to P450 1A2 WT, three
1A2 mutants and P450 1A1 WT. ...................................................................116
Table 4.4. Dissociation constant (KD) for the binding of CPR to P450 1A2 WT,
three mutants and P450 1A1 WT. ..................................................................119
Table 4.5. Energy contributions table ................................................................................120

vii

Chapter 1

Structure-function relationship of cytochromes P450

1

1.1. Cytochromes P450
Cytochromes P450 constitute a large superfamily of heme-thiolate enzymes,
which are capable of oxidizing a wide variety of both exogenous and endogenous
chemicals.

They are universally present in living organisms and comprise an

evolutionarily homologous group bearing different levels of sequence identity [1].
Until September 7, 2007, as reported on the P450 homepage (http://drnelson.
utmem.edu/p450stats.2007.htm), the number of published P450 homologous
sequences was 7703, which showed an amazing 50% increase over those known in
2005.

Among them, the majority are from eukaryotes (animals - 2740, plants - 2675

and fungi - 1231), and fewer from prokaryotes (bacteria - 813, protists - 226 and
archaea - 18).

At the same time, the number of published crystal structures of P450s

is still very limited compared with the large amount of sequences available [2].
In addition to the sequence homology relationship, P450 enzymes can also be
divided into four classes based on how electrons from NAD(P)H are delivered to the
catalytic site.

Class I P450s require a flavin adenine mononucleotide

(FAD)-containing reductase and an iron sulphur redoxin for catalysis. The majority
of these P450s are water-soluble and usually come from prokaryotes. Another class
I group includes eukaryotic enzymes often involved in steroid biosynthesis and found
in mitochondrial membranes.

Class II P450s are associated with endoplasmic

reticulum (ER) of eukaryotes, and they need a NADPH- dependent P450 reductase for
catalysis [3].

Class III enzymes are self-sufficient and require no electron donor,

while P450s from class IV can receive electrons directly from NAD(P)H.
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1.2. Cytochrome P450 Structure
1.2.1. Bacterial Cytochromes P450
The first published crystal structure of a P450 enzyme was a ligand-free form of
P450cam resolved at a 2.20 Å resolution in 1986 [4].
version at a higher resolution [5] was published.

One year later, its updated
Henceforth, these P450cam

structures were used as the structural prototypes for the whole P450 superfamily for
several years until the crystallization of another P450 species, P450 BM3 [6], in 1993.
Afterward, the pace of solving new bacterial P450 structures has been drastically
accelerated resulting in many crystal structures, such as P450terp [7] or P450eryf
[8], thus greatly enriching the structural library of P450s.
In the meantime, the understanding that all P450 enzymes preserve a similar 3D
fold with only subtle differences has been gradually strengthened. The typical P450
fold usually includes two basics domains: α (helices B’, C, D, E, F, G, H, I, J, J’, K”, L,
heme, sheets β3-β4, C-terminus) and β (N-terminus, helices A, B, K’, and sheets
β1-β2) [9].

The core region accommodating the heme cofactor, I and L helices, and

the beta-bulge segment hosting the Cys ligand just prior to L helix are considered to
be highly conserved throughout all P450 species [10]. This strong preservation of
structure has made it possible to construct reliable homology models for other P450s
with unknown structures for a long time [11-13].

However, due to the extremely low

sequence identity (< 20%) between bacterial P450s and their microsomal homologues
[14], the accuracy of the predicted structure for the target protein was seriously
doubted, and the validity of using bacterial templates to build homology models of
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eukaryotic P450s was questioned.

1.2.2. Eukaryotic Cytochromes P450
For a long time, the membrane-associated microsomal cytochromes P450 have
not been amendable to crystallography.

With increasing understanding of interacting

residues involved in membrane anchoring [15, 16], in 2000, Williams et al. published
the first crystal structure of a class II microsomal P450, P450 2C5 [17].

The

N-terminus was truncated and additional mutations have been introduced into the F, G
loop regions of the protein in order to make it more soluble.

The determination of

P450 2C5 crystal structure has obviously marked a new era of homology model
construction, especially for eukaryotic microsomal P450s.

Quite soon, there were

many applications to building homology models for various microsomal P450
structures like P450 1A2 [18] or P450 2B1 [19].

Moreover, the progress regarding

the crystallization of additional eukaryotic enzymes continued.

Until April 2004, a

total of ten crystal structures for class II microsomal P450s has been successively
solved [20-27], which covers five types of P450s, namely P450 2C5, 2C9, 2C8, 2B4
and 3A4.

This significantly enriched the library of structural templates for P450s

and facilitated the construction of more reliable and accurate microsomal P450
structures.
1.2.3. The P450 Fold
Both bacterial (class I) and mammalian microsomal (class II) P450s, and even
P450 BM3 (class III) structures share a similar overall fold (Figure 1.1).
4

They are

(A) P450 2C5

(B) P450 cam

( C ) P450 BM3 heme domain

(D) P450 BM3

Figure 1.1. Typical 3D structures of bacterial and eukaryotic P450s
(A) P450cam (B) P450 2C5 (C) P450 BM3 heme domain (D) P450 BM3.
All pictures are drawn in VMD 1.86. The secondary structures of P450s are
rendered as cylinders or sheets and colored by index model ranging from red to blue
(N- to C- terminus). In (D), the structure of P450 BM3 displays the relationship
between heme (top) and FMN domains (bottom and green).
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all composed of similar amounts and types of major secondary structure components
(helices and sheets) with very little variation regarding the length or composition.
This conservation and uniqueness of P450s make homology modeling of P450s a
reliable method.
Interestingly, P450 BM3 is actually a chimera enzyme containing both the
heme-thiolate P450 domain and the FMN-containing reductase domain.

Therefore,

it could be employed as the ideal prototype for the construction of the complex
composed of a microsomal P450 and its reductase partner.

1.3. Catalytic Mechanism of Cytochromes P450
Cytochromes P450 catalyze the incorporation of a single atom of oxygen into a
substrate with the concomitant reduction of the other atom to water, as shown in the
following equation [28]:
RH +

O2

+

2e− +

2H+ → ROH

+

H2O

1.3.1. P450 Catalytic Cycle and the Intermediate Active Species (Cpd I)
The catalytic cycle of cytochromes P450 is shown in Figure 1.2 [29].

Initially,

the resting state of the enzyme is the ferric (Fe3+) complex (1) with a water molecule
as its sixth distal ligand. At that time, the iron is in a low-spin (LS).

When the

substrate (RH) enters the active site, it replaces the water molecule, which leads to the
formation of the five-coordinated ferric species (2) accompanied by the transition

6

Figure 1.2. The catalytic cycle of cytochrome P450
As adapted from Shaik and Visser, 2005 [29], seven possible intermediate species of
the heme iron including Cpd 0 and Cpd I have been shown.
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of the iron into a high-spin (HS) state.

This triggers the reductase partner to transfer

one electron to a P450 resulting in the reduction of complex (2) to the HS ferrous
(Fe2+) complex (3). The ferrous porphyrin is a good dioxygen binder, which makes
it easy to attach molecular oxygen and produce the LS ferrous-dioxygen complex (4).
The latter species is again a good electron acceptor and facilitates another electron
transfer from the reductase so as to form the twice-reduced ferric-dioxo species (5).
This ferric-dioxo complex is a good Lewis base and therefore easily undergoes
protonation to yield the ferric peroxide complex (6) that is usually referred to as Cpd
0.

This complex undergoes a second protonation and cleavage of the O-O bond with

the concurrent incorporation of the distal oxygen atom into a molecule of water and
the formation of a reactive high-valent iron-oxo complex called Cpd I. The next step
involves the abstraction of the hydrogen atom from the substrate by Cpd I followed by
the radical recombination step to produce a stable product which is subsequently
released. Binding of a water molecule to the heme iron regenerates the resting state
of the enzyme (1) to finish one complete catalytic cycle. Although many details
involved in each step are still not clear, this well-defined catalytic cycle is still widely
recognized and applied to help explain various phenomena in the studies of P450
function.

1.3.2. Rate Limiting Steps
The P450 catalyzed reaction is a multiple-step process.

The complicated

mechanism makes it difficult to determine the rate-limiting step for the whole

8

Figure 1.3. The “oxygen rebound” mechanism of cytochrome P-450 catalyzed
hydroxylations
Adapted from He and Montellano, 2004 [38].
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catalytic reaction.

Many steps like substrate binding [30], electron transfer [31],

hydrogen abstraction [32] or even product release [33] have all been implicated to be
the possible rate limiting step.

For hydroxylation reactions, the most typical

reactions catalyzed by cytochrome P450, a “rebound” mechanism is widely
recognized and C-H breaking (hydrogen abstraction) step is usually considered as the
rate limiting step.

This mechanism is strongly supported by KIE study [34] and DFT

calculations [35], although some researchers still challenge the possibility of existence
of the intermediate radicals because of their too short lifetimes [36].
Given the alkane hydroxylation reaction as an example, basically the “rebound”
mechanism [37] refers to an initial hydrogen abstraction followed by the rebound of
the alkyl radical onto the oxygen of the iron-hydroxo species. A brief illustration of
a typical reaction mechanism is shown in Figure 1.3.

This reaction pathway

involves three phases: (a) a C-H abstraction phase that leads to an alkyl radical
coordinated to the iron-hydroxo complex by a weak OH…C hydrogen bond, (b) an
alkyl rotation phase whereby the alkyl group achieves a favorable orientation for
rebound, and (c) a rebound phase that leads to C-O bond making and the
ferric-alcohol complexes.

In the LS state, once the correct orientation of the alkyl

group is achieved, the LS rebound leads, in a virtually barrier-free fashion, to the
alcohol.

Consequently, the hydrogen abstraction step is usually regarded as a major

rate-limiting step in P450 catalyzed hydroxylation [38].

Therefore, a linear

orientation of O…H…C triad in the transition state is required for the impending
rebound phase, although hydrogen abstraction barriers in alkane hydroxylation exhibit
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a high sensitivity to the donor property of the alkane and the C-H bond energy.

1.4. Functional Domains of Eukaryotic Microsomal P450s
1.4.1. Ligand Binding Domain
The concept of Substrate Recognition Sites (SRS) was first introduced by
Gotoh in 1992 [39] to identify the regions of amino acid sequence in P450s family 2
enzymes that might be able to directly interact with substrates.

This was done using

the sequence alignment between these eukaryotic P450s and P450cam, which was
already crystallized, and comparing substrate-contact residues.

Six SRSs were

identified in the amino acid sequence and classified based on their positions in the
tertiary structure.
The active site of a P450 is located on the distal side of heme and displays the
highest variability among P450 structures.

It includes the following secondary

structural elements (listed from N- to C terminus): B-C loop including B’ (SRS1), F
helix (SRS2), G helix (SRS3), I helix (SRS4), sheet after K helix (SRS5) and loop
after L helix (SRS6).

Although helices and sheets comprising the active site are

generally conserved among P450s, they differ in lengths and positions. An active
site of P450 1A2 is shown in Figure 1.4 using the crystal structure with a docked
inhibitor, α-napthoflavone.
In fact, SRS residues are not the only ones which can determine the ligand
selectivity. Residues located around the putative substrate/product access channels

11

Figure 1.4. Active site of P450 1A2
Residues within 10 Å of α-napthoflavone (α-NF) in the crystal structure of P450 1A2
(and above the heme plane) have been selected and displayed as a yellow ribbon.
Heme is colored in red and α-NF in green.
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have been also suggested to also play a role in allowing the entry of ligands to the
active site. Quite a few pathways have been discovered by computational methods,
such as thermal motion simulation (TMS) [40] or random expulsion molecular
dynamics (REMD) [41].

However, how these pathways affect the substrate

selectivity is still to be answered.

1.4.2. CPR Binding Domain
Eukaryotic microsomal cytochromes P450 require a FMN/FAD dependent
NADPH-cytochrome P450 reductase (CPR) as a redox partner for binding and
providing electrons during the catalytic cycle [42].

The reductase plays a crucial

role in P450-catalyzed reactions, and also makes the mechanism much more
complicated and hard to approach using the routine methods usually applied in
studying the active site.
In vivo, the amounts of P450 enzymes are usually in molar excess to those of
CPR, with the ratio of the two components at about 4:1 [43], which indicates that
under physiological conditions various P450s have to compete for CPR in order to
metabolize their respective preferred drugs. Therefore, understanding the interaction
details responsible for the binding affinity and electron supply capability of CPR is
essential for the drug-drug interactions research [44].
This has become more feasible when the first crystal structure of rat CPR was
solved in 1997 [45], followed by a more refined crystal structure (1.93 Å resolution,
1B1C.pdb) of the FMN domain of human CPR in 1999 [46]. These two structures
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exhibit an extraordinary similarity of its α-β-α architecture with only minor
differences in the position, number, and length of the helices relative to the central
β-sheet.
As to the interaction pattern between these two proteins, the only source we can
refer to for help is the structure of P450 BM3.

The fusion of FMN and heme

domains makes it a self-sufficient enzyme and obviously the ideal prototype for the
association mode of P450 and CPR [47].

The crystal structure of the complex of the

heme- and FMN-binding domains [48] shows that FMN domain is positioned at the
proximal face of the heme domain, which seems to represent the most efficient and
coupled electron pathway from FMN to the heme iron.

However, the crystal

structure of CPR does not allow for an easy formation of a eukaryotic P450-CPR
complex.

In fact, for the FMN domain of CPR to properly dock onto the proximal

face of the P450 exactly simulating the pattern demonstrated by P450 BM3 crystal
structure, there must be a large structural adjustment within CPR, which may involve
twisting of the flexible linker segment between FMN and FAD domains that exposes
the FMN domain to contact with the proximal face of P450 [49].
Site-directed mutagenesis studies combined with molecular modeling strongly
indicated that salt bridges and hydrophobic clustering may dominate the interactions
between P450 and CPR, with the specific residues involved dependent upon a specific
P450 [50-51].

There has also been some dispute regarding a possible

conformational change in a P450 on binding of CPR, which can lead to alterations in
activity and/or specificity [52-53].
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1.4.3. Membrane Anchoring Domain
Another characteristic of microsomal P450 enzymes is that they are
membrane-bound proteins, which makes them hard to crystallize.

In fact, that has

become possible only recently, when some ingenious modifications have been
introduced to make these proteins soluble enough for crystallization [16].

Initially,

only the N-terminus was considered as a trans-membrane part, which led to rounds of
failures in constructing soluble P450 proteins by truncating the N-terminus segment.
Only later there came the realization that some other regions, beside the N-terminus of
the P450, must exist and contribute to membrane association [15].

A lot of effort has

been expended into developing methods to make the protein soluble, while keeping it
as intact as possible to preserve activity [54-55].
Although there is still some uncertainty regarding exactly which residues are
involved, it is generally agreed that F, G helices and the F-G loop are partly involved
in membrane anchoring.

With this understanding, more than ten crystal structures of

eukaryotic P450s have been solved [55].

Those structures again shed some light on

the reconstruction of the membrane anchoring system.
Considering a vast variety of P450 substrates, including either hydrophilic or
hydrophobic compounds, it is strongly believed that the ligand entrance pathways
should be at least partly immersed in the membrane so that lipid molecules may play
some role in gating the entrance of substrates and/or the release of products.
Therefore, the elucidation of the relative orientations of P450 and CPR in the
membrane will facilitate the research on substrate selectivity and provide a foundation
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for constructing the complete quaternary P450 catalyzing system including the ligand,
P450, CPR and the membrane all together.
So far, restricted by the present technology, most studies only give indirect
evidence regarding P450-membrane association, such as the relative angles of the
heme plane of P450 from the surface of the membrane [56] and the size and
dimension of P450 in the membrane [57].
Besides aforementioned functional domains, it has to be noted that
oligomerization domains may be other important sites affecting significantly P450
functions [58].

Although only monomers are assumed to be present in most of the

experiments performed so far, it is still unclear how much error this simplification
may impose on the final results. Recently, attempts have been made to construct
novel models of oligomerization, which have been partially successfully at unraveling
some puzzling phenomena in experimental data [59].

1.5. Molecular Modeling Methods Used to Study P450 Structure-Function
Relationships
1.5.1 Overview of Molecular Modeling Methods Applied in Studies on P450
Structure- Function Relationships
With the rapid development of both computer hardware and software, it has
become practical to employ advanced computational strategies to investigate the
structure-function relationships of various functional domains of cytochromes P450.
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Traditional structure-based modeling strategy [60] usually requires protein structures
first.

Crystal structures at high resolution are certainly the best starting points, while

models created by homology modeling methods are still acceptable candidates. A
routine protocol involves the following steps: 1) molecular mechanics (MM) based
energy minimization (EM) to release the restraints introduced by homology modeling,
2) ligand-protein docking to locate the key residues involved with a certain
ligand-protein interaction, and 3) molecular dynamics (MD) to produce enough
ensembles to simulate the motion.

1.5.2. Homology modeling
Homology modeling, also called comparative modeling, is one of the most
important techniques that provide the protein structure when there is no crystal or
NMR structure available [61].

This technique builds a three-dimensional structure

of the target protein based on the known structure(s) of its homologous protein(s),
based on the premise that homologous proteins with similar sequences usually hold
similar 3D structures as well. Usually, there exist two major different ways of
constructing homology models.

The first method assembles the target protein by

joining small segments together, while the second approach extracts spatial restraints
from the templates and uses it to iteratively optimize the target structure.

In either

method, the quality of sequence alignment plays an essential role in deciding the
quality of the final structure.
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1.5.3. Molecular Mechanics
Molecular mechanics (MM) refers to the use of Newtonian mechanics to model
molecular systems.

It is also known as a force field method, since it calculates the

potential energy of the systems using force fields.

MM can be used to study small

molecules, as well as large biological systems with many thousands to millions of
atoms.

The major application of molecular mechanics is energy minimization,

which is the predominant structure optimization method, and is intended to find the
minimum energy conformation [62].

1.5.4 Molecular Dynamics
Molecular dynamics (MD) [65] is a form of computer simulation wherein
atoms and molecules are allowed to interact for a period of time under Newton’s laws.
Molecular dynamics generates configurations of the system that are connected in time
and so MD simulations can be used to calculate time-dependent properties.
Moreover, MD could be utilized as an energy optimization method to overcome the
local barriers and search for the global minimum of a structure.

The ensembles

produced during MD simulations represent various states of the molecule during a
given time period.

1.5.5. Ligand-Protein Docking.
The goal of ligand-protein docking is to predict the position and orientation of a
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ligand relative to its receptor protein.

Docking strategies can be divided into

topology or energy driven processes, and should be able to find the best binding
structure of the ligand in its target protein. The accuracy of the docking results
usually depends on many factors, especially the terms of ligand-protein interaction
energy included in molecular mechanics. Thus it is always advisable to choose
several conformations with lowest docking scores for further analysis instead of
selecting only the lowest one.

Considering the possible flexibility of molecules

interacting with each other based on the “induced fit” theory, some programs even
developed promising algorithms allowing both the ligand and the binding site of the
target protein to remain flexible [63].

In the last decade, docking methods have been

extensively utilized in structure-function relationship studies of cytochromes P450 to
predict key residues and to guide site directed mutagenesis [64].

1.5.6. Protein-Protein Docking
Protein-protein docking has been developed as one of the preliminary methods to
identify key residues on the interfaces of the interacting proteins. Algorithms to
search shape complementarities are still the major focus in this field, although some
additional energy terms have been taken into account to refine the interface.
Considering the size and complexity of the interface, it is very hard to correctly
predict all possibilities. Therefore, in most cases, this method is still utilized as the
preliminary method to detect potential residues involved in protein-protein
interactions.
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1.5.7. Other Methods.
Other methods like quantum mechanics (QM), QSAR including 3D-QSAR and
CoMFA, have been also utilized to explore more detailed aspects of ligand-protein
interactions of P450s [66]. A hybrid QM/MM method [67] is very promising, since
it can help to explain various phenomena in chemical reactions.

On the other hand,

pharmacophore-based methods like 3D-QSAR will help to configure the necessary
structural units for the improvement of drug design.

1.5.8 Summary
Generally, the abovementioned computational methods can be classified into two
major groups: ligand-based and receptor-based.

Ligand-based modeling methods

usually require the analysis of a series of ligands in order to induce the common
features of the binding site, while receptor-based modeling methods start from the
structure of the receptor followed by the detailed analysis of the ligand structure and
probably the protein-ligand interactions using a few test probes. Depending on the
aim of the project, sometimes these two methods are combined in order to obtain a
certain goal.

1.6. Cytochromes P450 1A1 and 1A2 – Previous Studies
Human P450 1A subfamily consists of P450 1A1 and 1A2 enzymes.

P450 1A1

is mainly expressed in lungs, while P450 1A2 is almost exclusively constitutively
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expressed in the liver [68].

Human P450 1A1 plays an important role in the

metabolic activation of chemical carcinogens.

The enzyme is able to oxidize

benzo[a]-pyrene and other polycyclic aromatic hydrocarbons to their toxic derivatives
[69].

P450 1A2 is responsible for the oxidative metabolism of drugs such as

theophylline, caffeine, phenacetin and colzapine.

Moreover, this enzyme has also

been shown to be involved in the metabolic activation of carcinogenic arylamines and
heterocyclic amines to produce reactive metabolites [70].

Interestingly, P450 1A1

and 1A2 share 72% amino acid sequence identity, while they display different
substrate specificities towards many chemicals such as 7-ethoxyresorufin (ERES) and
7-methoxyresorufin (MRES).
Our previous studies demonstrated that a number of residue substitutions within
the active site cavities of P450 1A1 and 1A2 led to changes in specificity of
alkoxyresorufin oxidation [71].

To further investigate the roles of these key residues,

several reciprocal active site mutants of 1A1 and 1A2 have been constructed and
evaluated

for

their

methoxyresorufin-O-dealkylase

(MROD)

and

ethoxyresorufin-O-dealkylase (EROD) activities [72]. The changes in the specificity
indicator, the EROD/MROD ratio, have been partially explained by the propensity of
the hydrogen on the oxidation site of resorufin derivatives to approach the ferryl
oxygen of the heme during a relatively short period (50-100 ps) of molecular
dynamics (MD) simulations [73].
The results of these studies provided some promising information.

Firstly, key

residues identified in the active site played an important role in the specificity changes.
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Secondly, short time MD simulations can provide rationale for these specificity
changes.

Thirdly, the homology models of P450 1A1 and 1A2 we constructed were

fairly “correct”, at least in the core region.

These findings laid a good foundation for

us to further explore various aspects regarding structure-function relationships of
these two enzymes.

1.7. Research Objectives and Overview of the Chapters
In this project, we intended to investigate enzyme-substrate interactions, the
interactions of P450s with P450 reductase (CPR) and the interactions of P450s and
the membrane. The central hypothesis is that substrate dynamics in the active site,
P450-CPR interactions and P450-membrane interactions determine enzyme
specificity. These interactions will be affected by the identity of P450 residues in the
active site, at the CPR binding site and the membrane binding site, and they could
define regio- and stereospecificty of a given P450.

This will be studied by a

combination of theoretical techniques including homology modeling and molecular
dynamics, and experimental approaches, including NMR, site-directed mutagenesis
and functional analyses.
In chapter 2, we have been further exploring the role of the five key active site
residues that are different between P450 1A1 and 1A2.

MD-based molecular

modeling methods have been used to predict which multiple mutants of P450 1A2
will show the highest shifts in specificity with respect to oxidation of resorufin
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derivatives. A combination of site-directed mutagenesis and functional assays has
been applied to confirm the prediction.
With several new crystal structures of eukaryotic microsomal P450s on hand, in
chapter 3, we described an advanced method of developing the secondary generation
of homology models of P450 1As.

This method not only incorporated the distances

restraints between the ligand and the protein from NMR T1 relaxation data, but also
utilized as much as possible the structural information from all the available crystal
structures of eukaryotic P450s.

Phenacetin and its metabolite acetaminophen have

been docked into these models again so as to discern the different binding modes
between P450 1A1 and 1A2 and hence further validate these homology models
themselves as well.
Chapter 4 contains studies of P450-reductase interactions using protein-protein
docking method to discover the key P450 1A residues involved in CPR binding.
This was followed by experimental verification using site-directed mutagenesis
combined with various biochemical assays.
In Chapter 5, we extend our study to investigate the potential membrane
anchoring modes by modeling the currently available crystal structure of P450 1A2
with explicit membrane as the environment. This can help us to determine the
proper binding mode of the P450, possible ligand access pathways and finally propose
a plausible P450 1A2 –reductase complex in the membrane.
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Chapter 2

The Application of Molecular Modeling for Prediction of Substrate
Specificity in Cytochrome P450 1A2 Mutants
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Abstract
Molecular dynamics (MD) simulations of 7-ethoxy and 7-methoxyresorufin
bound in the active site of P450 1A2 wild type and various mutants were used to
predict changes in substrate specificity of the mutants.

A total of 26 multiple

mutants representing all possible combinations of five key amino acid residues which
are different between P450 1A1 and 1A2, were examined.

The resorufin substrates

were docked in the active site of each enzyme in the productive binding orientation
and MD simulations were performed on the ES complex.

Ensembles collected from

MD trajectories were then scored based on geometric descriptors relating substrate
position with respect to the activated oxoheme cofactor.

The results showed a high

correlation between the previous experimental data on P450 1A2 wild type and single
mutants with respect to the ratio between 7-ethoxyresorufin-O-deethylase (EROD)
and 7-methoxyresorufin-O-demethylase (MROD) activities, and the equivalent in
silico E/M scores. Moreover, this correlation served to establish linear regression
models utilized to evaluate E/M scores of multiple P450 1A2 mutants.

Seven

mutants, all of them incorporating the L382V substitution, were predicted to shift
specificity to that of P450 1A1.

The predictions were then verified experimentally.

The appropriate P450 1A2 multiple mutants were constructed by site-directed
mutagenesis, expressed in E. coli, and assayed for EROD and MROD activities. Out
of six mutants, five demonstrated increased EROD/MROD ratio confirming modeling
predictions.
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Introduction
Cytochromes P450 constitute a large family of heme-thiolate monooxygenase
enzymes widely found in nature [1].

These enzymes are capable of catalyzing the

oxidation of a wide variety of both xenobiotic and endogenous compounds.
However, even closely related isoforms may exhibit different catalytic activities.
Human P450 1A1 and 1A2, the two major isoforms in P450 1A subfamily, share
72% amino acid sequence identity but display different substrate specificities.

P450

1A1 prefers to metabolize benzo[a]pyrene and other polycyclic aromatic
hydrocarbons (PAHs), while P450 1A2 favors the oxidation of heterocyclic and
aromatic amines [2, 3].

Likewise, they also exhibit different substrate specificities

with resorufin substrates like 7-ethoxyresorufin and 7-methoxyresorufin [4, 5].
Therefore, the P450 1A1/1A2 system provides a good model for exploring the basis
for functional differences between individual P450 enzymes.
The experimentally determined structure of a protein can provide valuable
insight into its function.

Homology modeling is an alternative method to obtain the

structure when the crystal structure is not available [6].

Molecular dynamics (MD)

simulations on the enzyme-substrate complex could provide information on whether
the substrate is sterically accessible for oxidation, which could be used for predicting
the activities of different isoforms.

Indeed, this type of approach has been applied to

predict the catalytic activities, coupling/uncoupling efficiency and substrate
specificity of several bacterial and eukaryotic P450s and their mutants [7-9]. Likewise,
using a homology model of P450 1A1 [10], we have successfully employed MD
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simulations on the enzyme-substrate complex to evaluate the productive binding
orientations of benzo[a]pyrene and fatty acids [11].

This application not only

rationalized the metabolite profiles of several P450 1A1 substrates but also indicated
that steric influence could be quantitatively evaluated using the MD-based steric
scoring approach.
Docking of resorufin substrates in the active site of the homology model of P450
1A1 suggested that residue Val-382 may play an important role in binding and
O-dealkylation of these substrates [10].

This was confirmed experimentally in

further studies with P450 1A1 V382L and V382A mutants [12].

We have also

examined the function of five key residues that are different between P450 1A1 and
1A2, and thus may affect enzyme specificity [13].

Indeed, residue replacement

resulted in different levels of specificity changes in reciprocal P450 1A1 and 1A2
single mutants, as indicated by the ratio of 7-methoxyresorufin-O-dealkylation
(MROD) to 7-ethoxyresorufin-O -dealkylation (EROD) (EROD/MROD ratio).
However, no single reciprocal mutation was capable of entirely conferring the
activities of one isoform onto another, and only residue substitutions at position 382
in both P450 1A1 and 1A2 led to the shift in specificity.
The objective of the present study was to investigate whether any multiple
mutations in P450 1A2 may convert the resorufin specificity characteristic of P450
1A2 to that of 1A1.

A total of 26 multiple mutants representing all possible

combinations of five key amino acid residues which are different between P450 1A1
and 1A2, were evaluated using molecular modeling methods, such as molecular
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dynamics, and modeling predictions were verified experimentally.

This type of

approach may help in the determination of P450 specificity.

Methods and Materials
Materials
The DNA sequencing and mutagenic oligonucleotide primers were synthesized
at the Sigma Genosys (Woodlands, Texas).

QuickChange site-directed mutagenesis

toolkit and StrataPrep plasmid miniprep kit were purchased from Stratagene (La Jolla,
CA). E. coli DH5α competent cells were obtained from Invitrogen Corporation
(Carlsbad, CA).

7-Methoxyresorufin, 7-ethoxyresorufin, resorufin, NADPH,

ampicillin, isopropyl-β-D-thiogalactopyranoside (IPTG), δ-aminolevulinic acid
(ALA), 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate (CHAPS),
dilauroyl-L-3-phosphatidyl choline (DLPC) and phenylmethanesulfonyl fluoride
(PMSF) were from Sigma (St. Louis, MO). Ni-NTA Agarose and gel extraction kit
were purchased from Qiagen (Valencia, CA).

All other chemicals used were of

analytical grade and were obtained from standard commercial sources.

Construction of Multiple Mutants of P450 1A2
This part of the study was mainly carried out by Rahul Deshmukh. The clones of
P450 1A1 WT, P450 1A2 WT and 1A2 single mutants, T124S, T223N, V227G,
N312L and L382V, were constructed previously [12, 13].

Double to quintuple P450

1A2 multiple mutants were created using pCWori+ plasmids containing the His-tag

35

P450 1A2 WT or its single mutants cDNA as templates [13]. QuickChange®
Site-Directed Mutagenesis Kit was used, and mutagenic primers were the same as
utilized previously for the construction of single P450 1A2 mutants [13].

A typical

protocol described in the QuikChange® mutagenesis instruction manual was used
with minor modifications.

The PCR conditions were adjusted as follows: 1 cycle at

95oC for 1-2 min, followed by 20-25 cycles of temperature cycling – denaturing at
95oC for 30 sec, annealing at 55-65oC for 40-60 sec, followed by extension at 72oC
for an additional minute.

The cycling was followed with a final extension at 72oC

for 10 min. The PCR product was then treated with restriction enzyme Dpn I to
digest the parental DNA template.
1-B supercompetent cells.

Post-digestion product was transformed into XL

The plasmid containing the mutant DNA was purified

using Qiagen® plasmid purification kit. The double mutants were constructed by
adding an additional mutation to the single mutants and the triple mutants were
constructed in a similar fashion from the double mutants. The mutations in the
plasmids were verified by nucleotide sequence analysis carried out at the Molecular
Genetics Instrumentation Facility, University of Georgia (Athens, GA).

Protein Expression and Purification
This part of the study was mainly carried out by Rahul Deshmukh and Meena
Sivaneri. The His-tag-containing P450 1A1 and 1A2 WT and 1A2 mutants were
expressed in E. coli DH5α cells and purified as previously described [13], except that
during the purification of P450 1A2 WT and mutants, 0.5 M KCl was added to the
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solubilization buffer.

The final purity of the enzymes was assessed by SDS-PAGE.

Western blots were performed using anti-human P450 1A1/1A2 (Oxford Biomedical,
Oxford, MI) and P450 proteins were visualized as described [14]. P450 content was
determined by reduced CO/reduced difference spectra [15] and protein was measured
by the method of using Folin phenol reagent [16].

P450 Activity Assays
This part of the study was also carried out by Rahul Deshmukh and Meena
Sivaneri. 7-Methoxy- and 7-ethoxyresorufin O-dealkylase activities of P450 1A1
WT, 1A2 WT and their mutants were assayed as described previously at 37ºC by
fluorometric detection of resorufin, using excitation and emission wavelengths of 550
nm and 585 nm, respectively [12, 13]. The reaction mixture contained 50 nM P450,
100 nM P450 reductase and 10 µM substrate in a 0.1 M potassium phosphate buffer,
and the reaction was initiated by the addition of 10 µl of 100 mM NADPH, as
described [12, 13].

Rat cytochrome P450 reductase was expressed in E. coli and

purified as described [12, 13].

The formation of resorufin was detected as the

increase of fluorescence intensity against time.

The reaction rate was quantified

with resorufin standards. All measurements were performed in triplicate.

Molecular Modeling Methods: General
Molecular modeling was performed on an SGI Octane workstation using the
InsightII software (Accelrys, San Diego, CA). The homology model of P450 1A2
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have been constructed previously [13]. The crystal structure of P450 1A2 (pdb code:
2hi4.pdb) was obtained courtesy of Dr. Eric F.
Institute, La Jolla, CA.

Johnson, The Scripps Research

Minimization and molecular dynamics (MD) simulations

were performed using the Discover module of InsightII, with the consistent valence
force field (CVFF) supplemented with parameters for heme and ferryl oxygen [17,
18].Trajectory data were extracted using the Analysis module of InsightII and graphed
with Origin 8 (Northampton, MA).

MD Simulations with P450 1A2 WT and Mutants
The structures of P450 1A2 mutants were obtained by the replacement of
selected amino acids in the homology model of P450 1A2 followed by 500 iterations
of energy minimization using steepest descent gradient, essentially as described
earlier [12, 13].

7-Methoxy- and 7-ethoxyresorufins were previously docked into the

active site of P450 1A2 using the Affinity module of InsightII [13].

These

enzyme-alkoxyresorufin complexes served as the starting point for the subsequent
dynamic docking phase which refined the position of the substrate in the productive
binding orientation.
Dynamic docking involved 5 ps constrained MD simulations at 300 K.

During

that period, only the substrate and protein residues within 15 Å from the substrate
were allowed to move.

The non-bond interaction cutoff was set at 15 Å, a

residue-based non-bond list cutoff was 16 Å, and the distance dependent dielectric
was used. The distance between the ferryl oxygen and one of the hydrogens to be
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abstracted was restrained to 2.75-3.25 Å with a restoring force (k = 100 kcal·mol-1·Å-2)
applied to keep the oxidation site close to the ferryl oxygen.

Another distance

restraint of 4.10-4.35 Å between the carbon atom at the oxidation site and the ferryl
oxygen (C…O) was applied concurrently to keep the angle (C−H…O) as close as
possible to linear [18].
In the second part of MD simulations, all the restraints were abolished and the
substrate was allowed to move freely for the subsequent 50 ps.

Simulation

conditions were exactly as described above.

Sampling and Scoring of Productive Binding Orientation
The coordinates of each enzyme-substrate complex were saved every 250 fs
giving the total of 120 MD frames obtained following the initial 10 ps of dynamic
docking. All trajectories were examined with the Analysis module of InsightII.

To

score the likelihood of hydroxylation, each sampled frame of a given
enzyme-substrate complex was evaluated using different sets of geometric criteria.
The productive orientation of the substrate is usually defined by two parameters:
1) the distance, r, between the hydrogen atom at the oxidation site of the substrate,
and the ferryl oxygen atom (H…O distance), and 2) the angle, θ, between the ferryl
oxygen, hydrogen atom to be abstracted, and the carbon at the oxidation site (C−H…O
angle).

Since the linear transition state is assumed for hydrogen abstraction to occur,

ideally, the distance should be close to 3 Å and the angle is postulated to be 180° (Fig.
2.1-A).
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In this work, we used four types of criteria to define an effective score or “hit”.
Criterion P defined a hit as a frame in which the distance r was equal to or smaller
than 3 Å (r ≤ 3.0 Å), while criterion PM combined the condition on distance r with
the condition on angle θ, required to be larger than 135° (r ≤ 3.0 Å and θ ≥ 135°).
Less stringent criterion Q required the distance r not to exceed 3.5 Å, and criterion
QN added the requirement on angle not to exceed 120° (r ≤ 3.5 Å and θ ≥ 120°).

An

example of such an evaluation is shown in Fig. 2.1-C and 2.1-D, where criterion QN
is used to assess hits, represented by frames located within the grey region.
This procedure was applied to all single and multiple mutants complexed with
either 7-ethoxy- or 7-methoxyresorufin.

The “E/M score” representing in silico

specificity was defined as the ratio of hits obtained with 7-ethoxyresorufin to those
obtained with 7-methoxyresorufin.

Prediction of Substrate Specificity of P450 1A2 Multiple Mutants
The E/M scores obtained for single mutants were used to construct a linear
regression model that linked these results with experimental specificity expressed as
the EROD/MROD ratio defined previously [13].

The best correlation between the

two was seen for criterion P, with R2 equal to 0.9612 (p < 0.001), and for criterion QN,
where R2 = 0.9097 (p < 0.001).

Therefore, these two criteria were used for

prediction of specificity in multiple 1A2 mutants. The specific equations were as
follows:

40

A

B
6.0
H1

H2

5.0

r (Å)

4.0
3.0
2.0
1.0
0.0
0

180

10

20

30

40

50
H1

H2

θ (degrees)

150
120
90
60
30
0
0

10

20

30

40

50

Time (ps)

C
H1

H2

H1

θ (degrees)

θ (degrees)

120
90
60

1.0

2.0

3.0

4.0

5.0

6.0

7.0
H1

90
60

H2

0
0.0

8.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

180

H3

150

H1

150

120

θ (degrees)

θ (degrees)

120

30

30

90
60
30
0
0.0

H2

150

150

0
0.0
180

D

180

180

H2

H3

120
90
60
30

1.0

2.0

3.0

4.0

5.0

6.0

7.0

0
0.0

8.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

r (Å)

r (Å)

Figure 2. 1. A scheme for MD-based scoring of productive binding orientations with 7-ethoxyresorufin
as a substrate using a geometric criterion QN (r ≤ 3.5 Å and θ ≥ 120o).
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8.0

A:

Productive binding orientation of 7-ethoxyresorufin showing the two

geometric parameters, r and θ.

r is the distance between the hydrogen to be

abstracted and the ferryl oxygen; θ is the angle between ferryl oxygen, hydrogen
atom to be abstracted, and the carbon at the oxidation site.
B:

Plots of r and θ for hydrogens of the substrate that may be abstracted over 55

ps of MD trajectory in P450 1A2 WT.

H1 of 7-ethoxyresorufin is blue and H2 is

red; grey regions indicate where criterion QN is satisfied with respect to distance r
and angle θ.
C:

Ensemble of substrate orientations described by r and θ, sampled from 120

frames after 10 ps MD simulations in P450 1A2 WT.

The top panel represents

7-ethoxyresorufin (H1: red, H2: blue) and the bottom one is 7-methoxyresorufin (H1:
red, H2: blue, H3: green).

The grey region indicates where the geometric criterion

QN is satisfied.
D:

Similar plots as in C, except that the enzyme is P450 1A2 L382V.

42

for criterion P:
Predicted Specificity = 0.3900 (±0.0658) + 0.0138 (±0.0014) x E/M score
and for criterion QN:
Predicted Specificity = 0.2961 (±0.1093) + 0.1470 (±0.0231) x E/M score
Predicted specificity was expressed as predicted EROD/MROD ratio.

Comparisons with the Crystal Structure of P450 1A2
The homology model of P450 1A2 has been compared with the recently
available crystal structure of this enzyme [21]. The RMSD between the crystal and the
model has been measured by superimposing the backbones of the two structures using
different regions as a basis.

These included: a) overall structure, b) the active site

region, and c) the previously mentioned five key residues only.

The active site was

defined as a region containing residues within 10 Å from docked 7-ethoxyrersorufin,
and key residues were T124, T223, V227, N312 and L382.
7-Ethoxyresorufin and 7-methoxyresorufin were placed in the crystal structure of
P450 1A2 WT in positions similar to those in the homology model.

MD simulations

of enzyme-substrate complexes were performed in the same way as with the
homology model and the results were analyzed as described above, by counting hits
using different geometrical criteria.
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Results
Substrate Mobility in the Active Site of P450 1A2 WT and Single Mutants
Our previous studies with P450 1A1 and 1A2 reciprocal active site mutants
demonstrated that the replacement of a single residue may affect the specificity of
alkoxyresorufin metabolism (Liu et al., 2004). In particular, mutations at position
382 in both P450 1A1 and 1A2 shifted substrate specificity from one enzyme to
another. However, none of the single residue substitutions at positions 124, 223, 227
and 312 (location in the 1A2 sequence) completely interconverted P450 1A1 and 1A2
specificities [13].

Therefore, the goal of our present studies was to identify multiple

mutants in which the specificity of one enzyme was fully conferred to another.
In the first part of this project, we used molecular modeling methods, in
particular molecular dynamics (MD), to make predictions concerning the results of
multiple residue substitutions in P450 1A2.

Initially, P450 1A2 WT and its five

single mutants, which were investigated earlier [13], were selected as the training set
for MD simulations in order to provide information regarding specificity descriptors.
Molecular dynamics simulations were used both as a part of the docking strategy
to refine the substrate orientation in the active site, and as a means to predict the
product profile, similar to our previous work [11].

Thus, following the energy

minimization, the first 5 ps of restrained MD served to optimally place an
alkoxyresorufin in a productive binding orientation.

Figure 2.2-A shows the

resulting orientation of 7-methoxy- and 7-ethoxyresorufin in the active site of P450
1A2, with five key residues, T124, T223, V227, N312 and L382, displayed.
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A

B

Figure 2. 2.

The active site of P450 1A2.
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A:

7-Ethoxyresorufin (green) and 7-methoxyresorufin (orange) docked in the

productive binding orientation in the active site of the P450 1A2 WT homology model.
Five key residues have been displayed in blue as sticks, with their Cα shown as CPK.
Heme is shown in red.
B:

The comparison of the homology model and the crystal structure of P450 1A2.

The two structures have been superimposed using the backbones of the active site (10
Å around 7-ethoxyresorufin) as a basis.
structure is magenta.

The homology model is blue and the crystal

The five key residues in the crystal structure are brown.

46

The productive binding orientation has been defined by two geometric parameters, r
and θ, as illustrated in Fig. 2.1-A (see also Materials and Methods). During 5 ps of
dynamic docking, the distance, r, between the ferryl oxygen of the heme and the
hydrogen atom of the substrate to be abstracted was restrained to 3.0 Å
remained fairly constant (see Fig. 2.1-B).

and

In contrast, the angle, θ, between the

ferryl oxygen, hydrogen atom to be abstracted, and the carbon at the oxidation site,
alternated between 120° and 180° (Fig. 2.1-B), which indicated that the direct
distance restraints on O…H performed better than the restraint on angle.
The transition from the restrained state to the free moving state was achieved
over 5 ps.

For each enzyme-substrate complex, 120 frames from unrestrained MD

(productive phase) were then collected starting at 10 ps time point.

In most cases,

after removing the restraints, the substrate moved rapidly into another, more stable
orientation where it remained throughout the remainder of the simulation.

This led

to sudden and radical changes in relevant distances and angles, followed by a
reasonably steady phase of equilibrium, as illustrated in Fig. 2.1-B.
A detailed analysis of the geometrical parameters was performed for each
snapshot of every enzyme-substrate complex to evaluate the tendency of the ligand to
remain in the productive binding orientation during the productive dynamic phase.
Each enzyme-substrate complex displayed a unique characteristic MD “fingerprint”
regarding the distances and angles related to the productive binding orientation.
Two examples are shown in Fig. 2.1-C and 2.1-D.

For instance, for the P450 L382V

mutant, both hydrogens at the oxidation site of 7-ethoxyresorufin remained at about 3
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Å from the ferryl oxygen, while all hydrogens of 7-methoxyresorufin were much
farther away (Fig. 2.1-D), in agreement with our earlier findings [13].

Overall, in

this mutant, 7-ethoxyresorufin showed a greater preference to occupy a productive
binding orientation than 7-methoxyresorufin.

Specificity of 7-Methoxy and 7-Ethoxyresorufin Oxidation by P450 1A2 Single
Mutants
In our previous work [13] we expressed the specificity of various P450 1A1 and
1A2 mutants in terms of the ratio of 7-ethoxyresorufin O-deethylation to
7-methoxyresorufin O-demethylation (EROD/MROD ratio). This approach allowed
us to successfully evaluate alterations in activity upon residue substitution and the
degree to which the activity of one enzyme was conferred upon another. Therefore,
we also used the EROD/MROD ratio as a measure of enzyme specificity in the
present work.
Essentially, the EROD/MROD ratio was expressed in terms of its in silico
equivalent, the E/M score, which represented the number of “hits” for
7-ethoxyresorufin divided by the number of “hits” for 7-methoxyresorufin.

The

“hits”, i.e., the number of conformers with the substrate occupying the productive
binding orientation, were derived from the analysis of the productive phase of MD
simulations using four sets of different criteria with respect to distance r and angle θ.
Criteria P (r ≤ 3.0 Å) and PM (r ≤ 3.0 Å and θ ≥ 135°) were more stringent than
criteria Q (r ≤ 3.5 Å) and QN (r ≤ 3.5 Å and θ ≥ 120°), and criteria PM and QN
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included the conditions on both distance and angle (see Materials and Methods).
Table 2.1 shows the number of hits for the two substrates and the resulting E/M
scores for various P450 1A2 single mutants. Depending upon the set of criteria used
in counting hits, the E/M scores may vary widely. Usually the hit was a positive
integer with very few exceptions when no hits were found, such as for the
7-methoxyresorufin−P450 1A2 N312L complex.

For most mutants, E/M scores

were low and similar to the scores obtained for the WT 1A2, which correlated well
with experimental specificity. In contrast, the score obtained for the 1A2 L382V
mutant was much higher, as was the corresponding EROD/MROD ratio, consistent
with our previous findings [13].

This general agreement between the in silico

descriptors and experimental results allowed us to construct linear regression models.
As shown in Figure 2.3, the specificities of single 1A2 mutants as predicted by the
models were very close to the experimental ones, confirming good correlations.
Therefore, the models were subsequently used to predict EROD/MROD ratios for
multiple mutants, as detailed in Materials and Methods.

Specificity of 7-Methoxy and 7-Ethoxyresorufin Oxidation by P450 1A2 Multiple
Mutants
In order to determine which multiple substitutions of five key residues in P450
1A2 could potentially lead to the shift in specificity towards that of P450 1A1 WT, we
performed MD simulations with all possible multiple mutants.

Figure 2.4 shows the

schematic tree structure of all possible combinations of mutations containing one
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Table 2 1. Geometric analysis of the molecular dynamics results for the wild type
and five single mutants of P450 1A2.
Criterion Pa

Enzyme
type

Criterion PM

Criterion Q Criterion QN Experimental
Specificity

No. of Hits:
1A2 WT ERES

32

0

89

8

MRES

21

7

67

33

1.52

0

1.33

0.24

ERES

29

2

89

7

MRES

15

0

59

4

1.93

2b

1.51

1.75

ERES

21

0

59

4

MRES

21

6

77

24

E/M score

1

0

0.77

0.17

ERES

22

3

85

5

MRES

29

6

100

16

0.76

0.5

0.85

0.31

ERES

23

1

89

4

MRES

0

0

0

0

23b

1b

89b

4b

ERES

114

6

212

32

MRES

1

0

5

3

42.4

10.7

E/M score

0.4

No. of Hits:
T124S

E/M score

0.6

No. of Hits:
T223N

0.4

No. of Hits:
V227G

E/M score

0.4

No. of Hits:
N312L

E/M score

0.5

No. of Hits:
L382V

E/M score

b

6

114

Hits represent the MD frames were the substrate, 7-ethoxyresorufin (ERES) or
7-methoxyresorufin (MRES), was in the productive binding orientation, as evaluated
by various criteria.

E/M score is the ratio of hits for ERES to those for MRES.
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2.0

a

Criterion P: r ≤ 3.0 Å; PM: r ≤ 3.0 Å & θ ≥ 135°; Q: r ≤ 3.5 Å; QN: r ≤ 3.5 Å & θ ≥

120°.
b

The details are in Materials and Methods.

One hit was assigned to the denominator to replace 0.

Boldface represents the scores used to construct a linear regression model. The
details are described in Materials and Methods.
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Predicted specificity 1
Predicted specificity 2
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23N
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12
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82V
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P450 1A2 WT and single mutants

Figure 2.3. Experimental and predicted specificity for P450 1A2 WT and five
single mutants.
The specificity was expressed as EROD/MROD ratio. Two linear regression
models were used to calculate predicted specificity: predicted specificity 1 was
based on criterion P (r ≤ 3.0 Å), while predicted specificity 2 was based on criterion
QN (r ≤ 3.5 Å and θ ≥ 120o).
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Figure 2.4. The schematic tree structure of possible combinations of mutations
containing a L382V substitution.
A total of 15 multiple mutants: 4 double, 6 triple, 4 quadruple and 1 quintuple
mutant, is possible in this case. Similar trees were constructed for other mutations.
After removing repeated combinations, this gave a total of 26 multiple mutants
containing all possible mutations of the five key residues.
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substitution, namely Leu-382→Val.

The number of mutants with this particular

amino acid replacement, varying from double to quintuple, was fifteen, and, when this
procedure was repeated for all five key residues, the total number of all possible
mutants, excluding repeated combinations, rose to twenty six.

The MD simulations

were performed with all these mutants using exactly the same protocol as applied in
the case of P450 1A2 WT and single mutants (see Materials and Methods).

The

results were then evaluated using criteria P, PM, Q and QN, as described for the single
mutants.
The E/M scores were used to classify the mutants with respect to the possibility
of a significant shift in substrate specificity.

The in silico descriptor of P450 1A2

L382V, a mutant known to display a considerable shift in specificity, served as a
reference to select likely multiple mutant candidates.

As shown in Table 2.2, seven

out of 26 mutants had E/M scores equal to or above 80% of that for the L382V mutant,
and were thus predicted to display a similarly high shift in specificity. Furthermore,
these predictions were upheld with all four geometric criteria.
consideration

were

T124S-T223N-L382V,
N312L-L382V.

T124S-L382V,

T223N-L382V,

T124S-N312L-L382V,

The mutants under
V227G-L382V,

T223N-N312L-L382V

and

Thus, all the multiple mutants predicted to significantly alter

specificity had to include the substitution of Leu-382→Val, which further confirms
the exceptional role of this residue in producing specificity shifts from P450 1A2 to
1A1 and vice versa, with alkoxyresorufin substrates [13]. Interestingly, the quintuple
mutant, T124S-T223N-V227G-N312L-L382V, was not predicted to display altered
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Table 2.2. In silico E/M scores for the P450 1A2 multiple mutants predicted to
display large shifts in specificity.

Enzyme type

E/M score
(Criterion P)

E/M score
(Criterion PM)

E/M score
(Criterion Q)

E/M score
(Criterion QN)

T124S-L382V

105

11

45.3

23

T223N-L382V

93

10

183

51

V227G-L382V

92

22

40.8

31.5

T124S-T223N-L382V

102

14

60.7

56

T124S-N312L-L382V

101

9

37.2

38

T223N-N312L-L382V

109

10

38.4

45

N312L-L382V

112

9

63.7

37

L382V*

114

6

42.4

10.7

*L382V is used as a reference. All selected multiple mutants demonstrated an E/M
score that was 80% or more of that for L382V. See Results for details.
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specificity.
The MD-derived E/M scores were used to calculate the values of EROD/MROD
ratios for selected 1A2 multiple mutants based on two linear regression models
constructed for the single mutants (see the previous section). The extrapolated ratios
then served as a basis for the comparison with the experimental values.

Experimental Validation of Modeling Predictions
By employing modeling, we have significantly reduced the number of P450 1A2
multiple mutants, from twenty six to seven, needed for further experimental studies.
Six out of seven multiple mutants have been successfully created by site-directed
mutagenesis and were active in biochemical assays following purification.

The

double mutant V227G-L382V has not been successfully expressed.
Overall, mutant enzymes differed in expression levels and activities, as also
noted previously (Liu et al., 2004).

For example, P450 content of purified

preparations varied from ~1 to 60 nmol/ml, and specific content was from 0.2 to 60
nmol P450/mg protein, with holoenzyme in the range of 1-32% (data not shown).
Table 2.3 shows the activities and EROD/MROD ratios for various multiple mutants.
Due to a considerable variability in the levels of activities, the EROD/MROD ratio is
the best discriminator among the mutants, in agreement with our previous findings
[13].

It should be noted that the EROD/MROD ratios for the P450 1A2 WT and the

L382V mutant were 0.32 and 2.27, respectively (Table 2.3), displaying a slight
difference when compared to the previous values of 0.4 and 2.0 (Table 1) [13].
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Minor variations of that kind can be expected between different enzyme preparations.
Table 2.4 shows a comparison between the predicted and experimental
EROD/MROD ratios for the selected P450 1A2 multiple mutants. As mentioned
above, the predicted specificities were extrapolated from two linear regression models,
which established a correlation between in silico E/M descriptors and experimental
EROD/MROD ratios using P450 1A2 WT and its five single mutants (see Materials
and Methods).

Five out of six multiple 1A2 mutants have demonstrated the expected

high shift in specificities from P450 1A2 towards 1A1, with the exception of the
double mutant, T124S-L382V (see also Table 2.3). Moreover, the linear model using
criterion P (r ≤ 3.0 Å) seemed to give much closer predictions than that using criterion
QN (r ≤ 3.5 Å and θ ≥ 120o).

In the case of the latter, the predicted specificity values

were all much higher than the experimental ratios (Table 2.4).

The comparison

between the experimental and predicted specificity using criterion P for the selected
P450 1A2 multiple mutants is shown in Figure 2.5.

Interestingly, in the case of the

double mutant T124S-L382V, both prediction models have yielded much higher
specificity than its experimental value of 0.34 (Table 2.4).

The experimental

EROD/MROD ratio for this mutant was thus comparable to that of the P450 1A2 WT
(Table 2.3).

Comparison of the Homology Model of P450 1A2 with the Crystal Structure
At the final stage of this project, the crystal structure of human P450 1A2 has
been solved [18]. Thus, it became necessary to compare the homology model of P450
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Table 2.3. Alkoxyresorufin O-dealkylase activities of P450 1A2 WT, the L382V
mutant and multiple1A2 mutants predicted to display large shifts in specificity.

Activity

P450 1A2

% WT Activity

EROD/MROD

ERODa

MRODb

EROD

MROD

Ratio

WT

2.6c

8.04

100

100

0.32

L382V

0.68

0.3

26.1

3.73

2.27

T124S-L382V

0.12

0.35

4.61

4.35

0.34

T223N-L382V

0.57

0.43

21.9

5.35

1.32

T124S-T223N-L382V

0.19

0.09

7.31

1.12

2.11

T124S-N312L-L382V

4.05

2.75

156

34.2

1.47

T223N-N312L-L382V

5.1

2.4

196

29.9

2.13

N312L-L382V

1.76

0.71

67.7

8.83

2.48

a

7-Methoxyresorufin O-demethylase activity
7-Ethoxyresorufin O-deethylase activity
c
O-dealkylase activity as nmol product min-1 nmol P450-1
b
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Table 2.4. Predicted EROD/MROD ratios and their experimental values for the
P450 1A2 multiple mutants predicted to display large shifts in specificity.

Enzyme type

Predicted
EROD/MROD
ratio
(Criterion P)

Predicted
EROD/MROD
ratio
(Criterion QN)

Experimental
EROD/MROD
ratio

T124S-L382V

1.84

3.60

0.34

T223N-L382V

1.67

7.79

1.32

T124S-T223N-L382V

1.80

8.53

2.11

T124S-N312L-L382V

1.78

5.88

1.47

T223N-N312L-L382V

1.89

6.91

2.13

N312L-L382V

1.94

5.74

2.48

L382V*

1.96

1.87

2.0

*L382V is used as a reference.
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Specificity (EROD/MROD ratio)

3

Predicted specificity
2.5

Experimental specificity

2
1.5
1
0.5
0

82V
-L3
S
24
T1

V
82V
82V
82V
82V
382
3
3
3
L
L
L
L3
L
L
L
L
N
2
12
23
23N
31
312
T2
N3
-N
-N
-T2
S
S
N
24
24
23
T1
T1
T2

P450 1A2 mutiple mutants

Figure 2.5. Experimental and predicted specificity for the selected multiple
mutants of P450 1A2. The specificity was expressed as EROD/MROD ratio.
The linear regression model used to calculate predicted specificity was based on
criterion P (r ≤ 3.0 Å).
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Table 2.5. The comparison of the crystal structure of P450 1A2 with the
homology model.

RMSD(Å)

All Residues

Conserved
Secondary
Structureb

Overall

4.44

3.46

2.60

2.46

T124

1.75

1.78

1.92

1.10

T223

2.71

2.68

2.22

2.40

V227

1.73

1.73

1.68

1.44

N312

3.93

3.93

4.09

3.92

1.79

1.53

2.11

L382

a

1.91

Active Sitec

Key
Residuesd

a

Root Mean Squared Deviation (RMSD) calculated from the Cα backbone of all
residues (residues 34-513)
b

RMSD calculated from the Cα backbone of conserved secondary structure
elements
c

RMSD calculated from the Cα backbone of active site residues (residues within
10 Å of 7-ethoxyresorufin docked in the crystal structure of human P450 1A2)

c

RMSD calculated from the Cα backbone of key residues (T124, T223, V227,
N312 and L382)
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1A2 with the crystal structure in order to validate our current study.
With respect to the overall structure, the homology model resembles closely its
structural template, P450 2C5.

This could be the inevitable drawback of the

homology modeling methodology itself.

As shown in Table 2.5, the overall RMSD

between the model and the P450 1A2 crystal was 4.4 Ǻ when all residues were
included in the superimposition. This seemingly large value is not that surprising,
since this type of comparison includes both structurally conserved regions (SCRs) and
non-SCR segments, especially loops on the protein surface, which are usually created
in a random fashion with a lot of variability.

Consequently, it would be much more

reasonable to compare directly the core regions containing most of the SCRs, which
are directly involved in the interactions with substrates; in this case, the RMSD value
is reduced to 3.5 Ǻ.

Structural comparisons were further performed using additional

functional sets as the criteria, including active site residues and the five key residues
currently under investigation (Table 2.5).

The environment formed by only the five

key residues and that produced by all active site residues had a similar structural
divergence of ~2.5 Ǻ and 2.6 Ǻ, respectively, much lower than a corresponding value
for the global protein structure.

This indicates that the active site containing the five

key residues is well constructed in the homology model and comparable with the
crystal structure, as shown in Figure 2.2-B.

Moreover, in either option of

superimposition, all of the five key residues except N312 display reasonably good
structural similarity, as indicated by small values of backbone RMSD (Table 2.5.
Figure 2.2-B).

Therefore, N312 may not be properly positioned in the homology
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model, which might have resulted in artificially high and extremely variable E/M
scores observed earlier with the single mutant P450 1A2 N312L (see Table 2.1).
The dynamic behavior of substrates bound in the active site of the crystal
structure has been also investigated using the protocol established for the homology
model.

As shown in Table 2.6, regardless of the criteria used, the number of hits for

7-methoxyresorufin was significantly higher than for 7-ethoxyresorufin, in full
agreement with experimental data.

However, the E/M scores are similar in both the

model and the crystal only in the case of criterion QN (r ≤ 3.5 Å and θ ≥ 120o). This
may indicate the inaccuracy of the homology model and/or the specific conditions
applied in the computer simulation and data analysis.
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Table 2.6. Geometric analysis of the molecular dynamics results for the wild type
P450 1A2 using either the homology model or the crystal structure
Enzyme
type

Criterion P

Criterion PM

Criterion Q Criterion QN Experimental
Specificity

No. of Hits:
1A2 WT ERES
(Homology) MRES
E/M score

32
21
1.52

0
7
0

89
67
1.33

8
33
0.24

0.4

No. of Hits:
1A2 WT ERES
(Crystal)
MRES
E/M score

0
137
0

0
10
0

27
211
0.13

26
49
0.53

0.4

Hits represent the MD frames where the substrate, 7-ethoxyresorufin (ERES) or
7-methoxyresorufin (MRES), was in the productive binding orientation, as evaluated
by various criteria. E/M score is the ratio of hits for ERES to those for MRES.
a

Criterion P: r ≤ 3.0 Å; PM: r ≤ 3.0 Å & θ ≥ 135°; Q: r ≤ 3.5 Å; QN: r ≤ 3.5 Å & θ ≥
120°. The details are in Materials and Methods.
b

One hit was assigned to the denominator to replace 0.
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Discussion
In the current work, we used molecular modeling methods to predict the changes
in specificity of P450 1A2 toward alkoxyresorufin substrates upon introducing
multiple residue substitutions simultaneously in the active site.

The objective was

two-fold: to determine which residue combinations could completely interconvert the
specificity from P450 1A2 to 1A1, and to develop a fast computational method for
prediction of substrate specificity. Among twenty six possible multiple mutants,
ranging from double to quintuple, the molecular dynamics-based scoring method
predicted seven of them to shift specificity. Five predictions were further confirmed
experimentally by site-directed mutagenesis and biochemical assays.
These studies follow our previous work concerning the importance of five active
site residues that are different between P450 1A1 and 1A2 [13].

Based on those

findings, only mutations at position 382 shifted specificity from one enzyme to
another using alkoxyresorufins as substrates. Similarly, our present results indicate
that all mutations that likewise affect specificity contain a substitution at this position
(Table

2).

The

only

exception

was

the

quintuple

mutant,

T124S-T223N-V227G-N312L-L382V, which, contrary to expectations, was not
predicted to display altered specificity.

Moreover, no multiple P450 1A2 mutant

exhibited substrate specificity characteristic of P450 1A1.

This further strengthens

the idea that the specificity is not simply determined by a linear combination of these
five substitutions, but other residues, outside of the active site, must be taken into
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account. Similar conclusions were reported in earlier studies with single mutants of
other related isoforms, such as P450 2B1 and 2B2 [19], and 2B4 and 2B5 [20].
Moreover, in the P450 2B4 and 2B5 system, multiple active site mutations were not
sufficient to fully interconvert activities [21], analogous to our studies.
In the case of P450 1A1 and 1A2, a number of residues have been identified by
others as important for activity.

However, in most cases, the residues studied were

different than those we investigated here and in earlier work [12, 13].

For example,

more recently, Kim and Guengerich [22] reported that a triple mutant,
E163-V193M-K170Q, was five times faster than the wild type 1A2 in
7-methoxyresorufin O-demethylation.
the active site.

These residues, however, are located far from

Lately, a combinatorial approach has been applied by Taly et al. [23]

to discriminate between 1A1 and 1A2 using alkoxyresorufin substrates. However,
the residues we identified as important were not confirmed by this study[12.13],
possibly due to exclusion of this region of the sequence. In a very recent study,
Lewis and colleagues [24] described the construction of a homology model of P450
1A1 based on the structure of P450 1A2, and confirmed the importance of residues
124, 227 and 382 (numbers in 1A2) for binding of 7-ethoxyresorufin. Moreover,
Met-121 (Leu-123 in 1A2) was also suggested to have some contributions in binding
of this substrate [24].
A comparison of our homology model with the recently crystallized structure of
P450 1A2 [25] showed that the active site exhibits reasonably good structural
resemblance (Table 2.5, Figure 2.2-B). The placement of the four studied residues,

66

T124, T223, V227 and L382 is very similar; in contrast, the position of N312 appears
to be significantly shifted in the model. The latter phenomenon is likely responsible
for poor correlations between computational and experimental data concerning the
N312L mutant (see Table 2.1), and might have affected molecular modeling results
with other mutants.
In some respects, the current work is also a continuation of our previous studies
on regiospecificity of P450 1A1-mediated oxidations [11], where modeling
methodology was successfully applied to rationalize product profiles observed with
several 1A1 substrates. This earlier approach has been expanded so that we not only
used computational methodology for predictions concerning the specificity of
alkoxyresorufin oxidation, but also verified them experimentally.

As observed with

P450 1A1 oxidations, steric effects also seem to be of major importance in the case of
alkoxyresorufin oxidations by P450 1A2.

In this approach, we neglected substrate

electronic considerations, but, nevertheless, electronic factors can also provide
contributions. For example, they may account for differences in the number of hits
observed for a given enzyme with 7-methoxyresorufin as a substrate versus the
number of hits seen with 7-ethoxyresorufin (Table 2.1).

However, the E/M score can

serve as a basis for the comparison among different enzymes, and used as a descriptor
to correlate with experimental specificity.
The predictive power of this computationally-derived model is affected by the
length of the simulation and the number of samples collected for analysis. In our
case, after the minimization of the E-S complex, we applied restraints to force the

67

oxidation site of the substrate close to the ferryl oxygen, and then removed them to
evaluate the stability of the productive binding orientation. This approach has been
effectively utilized in our previous work [11]. Molecular dynamics with distance
restraints has also been successfully applied to investigate the metabolism of
sirolimus by P450 3A4 [9].

This, we believe, circumvents the need for long

simulations and gives this approach a potential to be routinely used as a rapid method
to predict specificity and/or product profile.
An important factor in molecular modeling when using homology models is the
accuracy of such a model, which depends to a large extent on the template used [26].
In that respect, the 1A2 model used in these studies, based on the structure of P450
2C5, can be expected to differ from the crystal structure of P450 1A2. As discussed
above, the active site structure of this homology model was quite similar to that of the
crystal.

Consequently, new models of highly related enzymes, such as P450 1A1,

should now be based on the crystal structure of P450 1A2. As reported recently, a
new 1A1 model was superior to the previous ones [24].
However, the question of structural “correctness” is not an easy one. Proteins
display structural flexibility, and in the case of P450s, this is confirmed by the
existence of multiple structures for the same isoform, that may display various
degrees of structural differences, often dependent upon the ligand bound [27, 28].
Thus, the basic P450 fold is very flexible, which is further supported by molecular
dynamics simulations that can “map the route” from one structure to another. For
example, in the case of P450 BM-3, MD simulations showed that binding of substrate
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may induce conformational shift leading to a structurally distinct P450-ligand
complex [29].

Therefore, we should take into account P450 flexibility and

reexamine the value of MD simulations.

Conclusions and Future Directions
The current work has successfully combined MD-based computational
predictions with their experimental verification, and the majority of predictions
concerning changes in substrate specificity in P450 1A2 multiple mutants were
confirmed.

This technique may thus provide a prototype for rapid evaluation of the

catalytic properties of different P450 isoforms.

Its application to the crystal

structures should further enhance the accuracy in the future.
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Chapter 3
Multiple Templates-based Homology Modeling of Human P450 1As
Using T1 NMR Restraints for the Refinement of the Active Sites
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Abstract
A new generation of homology models of P450 1A1 and 1A2 have been
successfully constructed using nine crystal structures for four species of eukaryotic
P450s as the structural templates.

The distance restraints between the hydrogen

atoms on the oxidation site of the ligand and the ferric iron of the heme, acquired
from NMR T1 relaxation experiments, have also been embedded to further delineate
the interactions between the ligand and the enzyme. This strategy is expected to
produce a more accurate homology model, which is particularly adapted to
accommodate specific ligands.

Further study employing molecular dynamics (MD)

based docking with these distance restraints has revealed the orientations of substrates
(phenacetin) and products (2-acetominophen) in the active sites of P450 1As. The
new model of P450 1A2 has also been compared with the old homology models
(based on only a single template P450 2C5) and validated using with the recently
published crystal structure of P450 1A2.
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Introduction
Cytochromes P450 constitute a large family of ubiquitous enzymes present in all
living organisms, including humans, which are responsible for the metabolism of a
wide range of both endogenous and xenobiotic compounds [1]. Since most clinical
drugs currently on the market are substrates for P450s, the exploration of
structure-function relationships of these enzymes will facilitate the understanding of
their ADMET (Absorption, Disposition, Metabolism, Excretion and Toxicity)
properties.
P450 1A1 and 1A2 are two major isoforms in the human P450 1A subfamily [1].
These two enzymes share a high sequence identity (72%), while still exhibiting fairly
divergent substrate specificity [2-3]. P450 1A2 is often found to be involved with
the metabolism of several heterocyclic and aromatic amines [4], including phenacetin.
The reaction it catalyzes with phenacetin, O-deethylation, has traditionally been
considered an index reaction for P450 1A2 [5], though P450 1A1 can also metabolize
phenacetin, but at a significantly lower rate.
For studying structure-function relationships of P450s, a structural model is
necessary and quite useful. Ideally, the three-dimensional atomic coordinates for the
P450 of interest should have been determined by X-ray crystallography or NMR
spectroscopic techniques. However, so far only a small fraction of the known P450s
have been crystallized, and their coordinates are available from the Protein Data bank.
Therefore, we still have to rely heavily on homology modeling techniques to construct
many other known P450 3D.

Homology models approximate an unknown structure

75

by using available homologous structures as templates.

The accuracy of the

homology models is thus heavily dependent on the number of homologous templates
available, their evolutionary similarity with the target (conservation), and the
quality/accuracy of the available template structures (crystallographic resolution,
distorted conformations in non-biological crystalline environments) [6].
Prior to the availability of a crystal structure of the eukaryotic P450 2C5
deposited in 2000, homology models of eukaryotic P450s were built based on the
crystal structures of distantly related prokaryotic P450s such as P450cam [7],
P450BM3 [8], P450terp [9], P450eryF [10] as templates.

Due to the extremely low

sequence identity between the prokaryotic structures and the eukaryotic P450
sequences of primary interest, homology model construction was plagued by both
weak templates (low sequence identity) and the resulting errors in the critical
sequence alignments.

Thus, the first crystal structure for a eukaryotic P450, released

to the public in 2000 [11], has provided a better template to develop new homology
models for P450 1As and other eukaryotic P450s [12-14].

Those models have been

further validated by various strategies including the successful prediction of key
residues involved with the metabolism and selectivity of some substrates [3].
In the next four years following the availability of the crystal structure of P450
2C5, more than nine eukaryotic P450 crystal structures have been solved [15-22].
There comes the challenge for updating the old homology models, which only use
P450 2C5 and/or other prokaryotic P450s as the templates.
The utilization of a single structure as a template is very risky since this
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profoundly biases the target sequence to resemble the template. This problem is
exacerbated when the sequence identity between the template and the target is low or
the template structure still has some unresolved structural problems (e.g., missing
coordinates for loops, excessively high B-factors).

The availability of multiple

templates can overcome this bias in the model construction. It can fill in the gap that
arises in any single template structure by providing bountiful structural templates for
making a choice, and a broader ensemble of target models (alternative conformers) for
evaluation based on experimental information [23].
Meanwhile, with the discovery of an open conformational structure of P450 2B4
[21], the possibility of multiple, functionally relevant conformations for a particular
P450 enzyme exists.

Binding of the ligand may mutually affect both the ligand and

the enzyme, which may lead to the configuration changes regarding the topology of
the active site or even perturb the global conformation of the enzyme.

These

findings strongly suggest that proper representation of the interactions between the
substrate and the active site may be required to better configure the topology of the
active site. Therefore, the incorporation of such information in the initial stage of
homology model building process could further improve the quality of the homology
model. This innovative idea has been applied to refine the homology models and has
yielded some useful results [24].
Modeller [25-26] is a homology model construction program that utilizes
various geometrical restraints during the homology model building process in order to
optimize the Probability Density Function (PDF) by minimizing the violation of the
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various restraints.

This approach makes it the most suitable program for both

extracting proper and adequate structural information from multiple structural
templates and shaping the active site by experimentally acquired geometrical distance
data as well [27].

In fact, in most cases, the major aim of constructing a homology

model for a protein target is to configure the topology of the active site and/or the
relative positions of some key residues to guide the subsequent experiments [28-29].
In this work, we have constructed and validated the second-generation homology
models of P450 1A1 and 1A2, which are based on nine known crystal structures of
eukaryotic P450s and include four species. The distance restraints from NMR T1
relaxation experiments have been used during the homology model construction
process and the subsequent ligand docking process to improve the quality of the
active site structural model.

Materials and Methods
Homology Modeling - General
With the recently available crystal structures of eukaryotic P450s as templates, the
second-generation homology models of P450 1A1 and 1A2 were constructed using
MODELLER 7.7 by applying a structure-based strategy [23]. Distances between the
hydrogens on the oxidation site of the substrate and the ferric iron of the heme, as
determined through NMR T1 relaxation measurements [27], were applied as
additional restraints during the model construction process.

These additional

constraints were imposed to direct the binding of phenacetin in the active site in a
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realistic way towards the experimentally suggested binding pose with respect to the
iron atom.

Meanwhile, a particular substrate-bound model, which is supposed to be

well adaptable for the bound phenacetin and its metabolites, has also been created.

Template Selection
Using CLUSTAL W 1.82 (http://www.ebi.ac.uk/clustalw/), a multiple sequence
alignment was performed on all the prokaryotic and eukaryotic P450 sequences with
currently available crystal structures.

Their evolutionary relationship is displayed as

a phylogenetic tree (Figure 3.1-B).

There was a great divergence in sequence

consensus between the prokaryotic P450s and P450 3A4 with our target sequences:
P450 1A1 and 1A2 (Figure 3.1-A). For that reason, only crystal structures of P450
2C5, 2C9, 2C8 and 2C9 were included as templates, providing nine independent
structures that included both ligand-bound and ligand-free forms for most of the P450
species (Table 3.1).

Structure-based Sequence Alignment of the Templates
The nine P450 templates were structurally aligned using the Homology module
of InsightII.

Alignment parameters were adjusted so that as much as possible

secondary structural elements could be included in the predicted Structurally
Conservative Regions (SCRs) [30] for all of the template structures. Then, based on
the results from the secondary structure prediction of P450 1A1 by PHD
(http://cubic.bioc.columbia.edu/predictprotein/) [31], we manually adjusted the
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A

B

Figure 3.1. Multiple sequence alignment of P450 1A1 with various prokaryotic
and eukaryotic P450s.
The alignment was performed by CLUSTAL W (1.82). The sequence alignment
score with P450 1A1 for each P450 species has been displayed in (A). Phylogenetic
tree is shown in (B).
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Table 3.1. List of the crystal structures of eukaryotic P450s used as the templates
Type

PDB
Code
1DT6

Name

Structure Description

Resolution(Å)

C5F

Mammalian Cytochrome P450 2C5

3.00

Date
Available
Jan-00

1N6B

C5S

Microsomal Cytochrome P450 2C5/3Lvdh With A Dimethyl Sulfaphenazole

2.30

Nov-02

1NR6

C5D

Microsomal Cytochrome P450 2C5/3Lvdh Complex With Diclofenac

2.10

Jan-03

2C8

1PQ2

C8F

Human Cytochrome P450 2C8

2.70

Jun-03

2C9

1OG2

C9F

Human Cytochrome P450 Cyp2C9

2.60

Apr-03

1OG5

C9F1

Human Cytochrome P450 Cyp2C9

2.55

Apr-03

1R9O

C9FL

P450 2C9 With Flurbiprofen Bound

2.00

Oct-03

1PO5

B4F

Mammalian Cytochrome P450 2B4

1.60

Jun-03

1SUO

B4I

Mammalian Cytochrome P450 2B4 With Bound 4-(4- Chlorophenyl)Imidazole

1.90

Mar-04

2C5

2B4
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alignment between P450 1As sequence and the fixed assembly of structurally aligned
multiple template structures using a combined sequence and structure alignment
strategy.

The following rules were invoked during the construction and editing of

the alignment (Figure 3.2): 1) the segment assumed to be a secondary structure unit of
P450 1As was accommodated into a SCR as much as possible; 2) each pair of aligned
sequences containing P450 1A and either of the P450 templates has been evaluated
using Dayhoff’s mutation matrix and the Engleman and Steitz’s hydrophobicity index
[23] to validate this choice of predicted SCR; 3) if a gap in the alignment was
inevitable, it was placed in the middle of the loop instead of interfering with the
continuity of a secondary structure unit; 4) in a few cases, when no satisfactory score
(usually, mutation index ≥ 0 and hydrophobicity index ≥ 100 were assumed as
acceptable) was found for any template, the nearby segments were combined,
shortened, or the representation with a relatively higher score was selected.

The

alignment results were further verified by comparison with the alignment between
P450 1A1 and P450 2C5 from a previous independent study [23].

Homology Model Construction
Phenacetin was constructed in the Builder module of InsightII (Accelrys, San
Diego, CA) and was treated as a block residue in MODELLER. The heme cofactor
of the target protein was aligned to that of P450 2C5 (C5F) from the templates.
Interatomic distances between hydrogens of phenacetin and the paramagnetic center
of Fe on the heme in P450 1As, as estimated by T1 NMR experiments, have been
imposed as distance restraints between the residing carbon of each particular
hydrogen and Fe (Figure 3.3). In the case of phenacetin bound in P450 1A1, four
distance restraints were obtained, with upper and lower bounds determined by the
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Figure 3.2.

Schematic diagram for the selection of templates.

The multiple alignment of nine templates and P450 1A1 sequence is displayed here to
show the results of template selection. Segments used as the structural templates by
Modeller for P450 1As homology model construction were highlighted in green or
yellow. The corresponding target sequence used the same color as those of its
templates. Residues of secondary structures are colored as follows: red (α-helix),
blue (β-strand), black (loop, turn, and random coil regions).
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P450 1A1
Distance (Å)

P450 1A2
C atom

Distance (Å)

C atom

4.90 (0.63)

C7

5.10 (0.81)

C7

4.62 (0.24)

C3

4.65 (0.34)
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4.65 (0.31)
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4.85 (0.43)
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>6.7
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4.78 (0.87)
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4.50 (0.24)

C8

4.83 (0.45)

C8

Figure 3.3. NMR T1 distance restraints used in Modeller.
These distances have been transformed into those between the ferric ion of the particular
P450 1A enzyme and the residing carbon of the chemically equivalent hydrogens in various
positions of phenacetin. Standard deviation from NMR experiments is shown in brackets.

86

calculated error in the T1 measurement.

For phenacetin bound to P450 1A2, five sets

of distance restraints were obtained.

These restraints were incorporated into the

model building process and thus provided phenacetin binding positions in agreement
with the measurements.
The ten lowest energy models, as ranked by the PDF violation scores
(MODELLER scoring function), were considered for further evaluation.

Backbone

alignment of the lowest energy models revealed a consistent folding for the ensembles,
with Cα RMSD < 0.60 Å for P450 1A1 and 0.66 Å for P450 1A2. In all models, the
helical transmembrane N-terminus was removed (residues 1-39) since no template
information was available for this region.

Homology Model Refinement
This part was mostly performed by Spencer S. Ericksen. Since folds were fairly
consistent among the ten highest ranking structures built with Modeller, the best
ranking model for each isoform was selected for refinement procedures.

Visual

inspection indicated that all secondary structures were present with no dramatic steric
clashes among structure elements. In InsightII, hydrogens were added and ionizable
side chains were protonated according to a pH 7.4 environment. CVFF potentials
were assigned to all the atoms and the model was subjected to a series of
minimization procedures consecutively, first on hydrogens, sidechains, then on all
protein with protein backbone tethered to its initial position
Then the system was explicitly solvated by a 10 Å shell of water.

All

hydrogens were minimized in this system, then water, then water plus sidechains.
Finally, a 500 ps MD simulation was performed with tethering forces applied to the
backbone to maintain initial positions. The tethering restraints were gradually
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diminished from 10 kcal•mol-1•Å-1 to 0 kcal•mol-1•Å-1 over the first 100 ps and
removed for the duration of the trajectory.

MD Docking with Application of T1 NMR restraints
This part was mostly performed by Spencer S. Ericksen. Both substrates,
phenacetin and acetaminophen, were built using the Builder module of InsightII.
Substrates were then geometry optimized by MOPAC AM1 level of calculation and
partial charges derived using AM1 Mulliken populations.

Initially the substrates

were manually placed into the active sites avoiding steric overlaps, then they are
docked using the Affinity module.

From 20 orientations yielded, the most

energetically favorable complexes was subjected to molecular dynamics (MD)
simulations and minimization with NMR-based distance restraints imposed.

To

reduce possible protein deformation resulting from restraint forces, the protein
backbone was again tethered to its initial coordinates by harmonic restraints.
Substrate protons were guided to suitable distances from the Fe atom by a gradually
strengthening harmonic restraint (k = 2-32 kcal/mol Å) over 4 picoseconds of MD.
The nonbond cutoff was set at 15 Å, a dielectric of 1 was imposed.

Residues further

than 10 Å from the initial substrate position were held fixed. After the MD run, the
structure was minimized with distance restraints with 500 steps of steepest descents
and 500 steps of conjugate gradients minimizations.

Results and Discussion
Template Selection
A total of thirty six SCRs (Structurally Conserved Regions) have been produced
after employing structural alignment on the selected structural templates by properly
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adjusting aligning parameters.

The SCRs covered cumulatively 87.3% of the lengths

of all the structural templates. It is observed that the major secondary structures like
α-helices and β-strands for all nine structural templates are well within these SCR
boxes except B’ helix and F, G helices, which are assumed to be the most flexible
regions and thus highly adaptable for ligand binding, entrance and possibly membrane
anchoring as well [32].
Gaps were only introduced into loop regions to avoid disrupting the secondary
structural elements.

Typically, when a gap arose, the neighboring SCR boxes

selected as the structural templates were shortened by a few residues so as to provide
enough space and flexibility for forming energetically unstrained linking loops.
Since P450 1As (P450 1A1:512, P450 1A2: 515) sequences are around 20 residues
longer than those of P450 2 family [33], most of the additional residues are found to
be inserted into the N-termini before the A helix to form the transmembrane segment,
while all the others were evenly inserted with the exception of the F-G loop.
Interestingly, the F-G loop of P450 1A1 is two residues shorter than its counterparts in
the P450 2B and 2C families, which indicated that it may tighten the ligand entrance
pathway there [34] and possibly prevent the entrance of bulky ligands.

The

sequence alignment between P450 1A2 and 2C5 also matches the previous one very
well, except some minor alteration regarding the position of gaps in B’-C loop and
H-I loop.

Since Modeller does not allow multiple structures with significant

structural divergence to be utilized as templates simultaneously, the specially designed
strategy here will assure that the program can work and the most structurally similar
templates could also be selected as well.

Homology Model Construction and Refinement
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Distance data derived from NMR T1 relaxation experiments are usually
interpreted as a time-averaged mean for all chemically-equivalent hydrogens, it is
advisable to choose a pseudo atom to represent this average.

For simplicity, in this

case, we chose the carbon atom connecting the chemically equivalent hydrogens to
represent the center of mass among a given set of chemically equivalent hydrogens.
Due to the limits of Modeller, BLOCK residues can only take inter-molecule
interactions into account, which means that phenacetin will be regarded as rigid body
with no flexibility during the homology model construction process.
The resultant structure after a few rounds of refinement did not deviate too
much from the generated structure with the lowest PDF violation score from Modeller,
which suggests that the output structures are of reasonable stereochemical quality and
could be directly used for molecular dynamics studies.

This is reasonable since

Modeller has already minimized the energy for each member of the output ensembles
using the CHARMM force field.
Interestingly, some distortion is evident in the middle of I helix for P450 1A1
homology model during the refinement by MD simulation, which apparently disrupts
the H-bonding in I helix.

The same phenomenon was also noted in the first

generation homology models of both P450 1A1 and 1A2 (derived from one P450 2C5
template). So far, it is not clear whether this kink is an artifact introduced by MD
simulations or it indicates really dynamically unstable regions participating
functionally in catalysis, although it has been reported to be commonly found in the
crystal structures of other P450 species as well [17, 35].

One possible explanation

for this could be that the superior length of this helix results in its tendency to be
easily disrupted after ligand binding which could be recreated by some intense MD
simulations.

On the other hand, it has been suggested that the helical kink might be
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required to accommodate or perhaps “sense” molecular oxygen at the distal, axial
position on the heme iron [36].

Homology Model Validation
The quality of a protein structure can be evaluated by many methods [37]. The
Ramachandran plot is used to graphically represent the feasibility of the observed
phi/psi backbone dihedrals with respect to the known population of dihedrals in
experimentally solved protein structures.

The plots here (Figure 3.4) gave an

indication that the new homology models are more representative of actual proteins
than the older models, especially for P450 1A2.
RMSD of overlapping Cα backbone is 4.866Å for the two generations of
homology models for P450 1A1, and 4.709Å for models of P450 1A2.

As depicted

in Figure 3.5, the degree of structural divergence and conservation have been
carefully illustrated and examined between the 1st and 2nd generation homology
models for each P450 1A species. The core regions including the active site and the
proximal face providing the contact surface for the CPR partner are much more
conserved than the exterior of the structure.

In general, most prominent divergences

are scattered in the following regions for both P450 1As:

loops after A helix, A/A’

helices, B’-C loop, D-E loop, C-terminus of G helix and G’ helix, I-J loop, K’’-L loop.
It appears that loops are still the major problematic regions in these homology models,
which is generally true of all homology models since loops are sometimes not
well-defined in the templates and tend to diverge in sequence even among closely
related proteins which produces errors in the alignment.
Comparing the models of P450 1A1 and 1A2 (Figure 3.6), the overall folds are
quite similar.

Superimposition based on the homology models of both enzymes
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New P450 1A1

Old P450 1A1

New P450 1A2
Figure 3.4.
P450 1As.

Old P450 1A2

Ramachandran plots for two generations of homology models of
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Distal Face (1A1)

Proximal Face (1A1)

Distal Face (1A2)

Proximal Face (1A2)

Figure 3.5. Comparison of the distribution of structural divergence between the
new and old homology models of P450 1A1/1A2.
The models are viewed from distal and proximal sides. Heme is displayed in blue
sticks, green indicates structurally conserved regions with low RMSD, red indicates
the highly divergent regions.
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Figure 3.6. The distribution of structural conservation and divergence between
the new homology models of P450 1A1 and 1A2.
Heme is displayed in blue sticks, green indicates structurally conserved regions with
low RMSD, while red indicates the highly divergent regions.
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using residues from 42 to 512 indicates that structural components after H helices are
also well conserved. In a paired sequence alignment of P450 1A1 and 1A2, it is
shown that after H-I loop, there are only two gaps, accounting for a total of three
residues, located in K’’-L loop and 4-1 β sheet. The gaps in these regions appear to
have little effect on the overall fold and positioning of the secondary elements.

We

did, however, note additional discrepancies between the homology models of P450
1A1 and 1A2 outside of the loop regions: (1) P450 1A1 lacks A’ and B’ helices, (2)
the orientation of the G’ helices deviates significantly between the models, and (3) I
helix of P450 1A1 is kinked in the middle. Of these structural discrepancies, besides
the A’ helix, all the others reside in the SRS regions, which are supposed to determine
ligand binding and recognition processes.
To validate our model building process, we compared our 1st and 2nd generation
models with the crystal structure of P450 1A2.

In this comparison, we observed

good agreement between the homology model and the crystal structure in terms of the
overall fold (Figure 3.7).

The relative orientation of all major secondary structural

units is fairly consistent with the notable exception of the A and A’ helices, whose
relative orientation suggests an error in the model in this region. However, it may be
postulated that A’ helix is a flexible part whose orientation/conformation is sensitive
to the location and orientation of the transmembrane N-terminus.

Another

interesting difference is the surprising distortion in the middle of F helix which occurs
in the crystal structure only. However, this is also reasonable since this region is
probably flexible in order to accommodate the binding ligand.
The quality of the model’s active site geometry was also evaluated by
comparison to the crystal structure of P450 1A2.

Five key residues, which we

identified earlier as critical to substrate recognition, were used as structural reference
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2nd Generation Homology Model

Crystal Structure

Figure 3.7. Comparison of the new homology model of P450 1A2 with the 1A2
crystal structure.
The proteins are displayed in cartoon style with major secondary structures labeled.
Heme is colored in red and the color is transformed from red (N-terminus) to blue (Cterminus).
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Table 3.2. The comparison of the crystal structure of P450 1A2 with the 2nd
generation homology model.
RMSD(Å)

All Residues

Conserved
2° Structure

Active Site

Key Residues

Overall

4.50

3.85

3.51

3.05

T124

8.46

8.21

7.69

4.81

T223

4.49

3.96

3.74

2.28

V227

2.61

2.17

1.92

0.48

N312L

1.99

2.34

2.52

4.06

L382V

1.06

1.18

1.33

2.50

RMSD between key residues was obtained by superimposing the backbone of
different functional groups.
All residues: residue 42-513
Conserved secondary structures: 2nd structures designated in pdb file 2hi4
Active site: residues within 10 Å of BNF in the crystal structure of human P450 1A2;
Key residues: T124, T223, V227, N312L, L382V;
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points (Table 3.2).

As observed with our previous 1st generation homology model of

P450 1A2, the alpha carbon (Cα) RMSD values gradually decrease in the following
order: 1) the entire backbone of the tertiary fold, 2) secondary structures, 3) the active
site and 4) the five key residues. It verifies the findings that the core structure is well
conserved structurally. We did note, however, that the there was a significant error
in the Cα positions of key residues T124 and T223, which were in fact smaller in the
1st generation model.

On the other hand, we see that the divergence at position

N312L is significantly reduced in the new model compared with that in the old model.
The persistence of significant divergences between the crystal structure and both
generations of models at the core of the enzyme is a strong indication that homology
model construction in P450s is quite good at predicting the global fold, but not the
relative positions of key active site residues.

In this sense, it is not clear which of

these two model generations better represents the active site topology.

However,

considering that those five key residues were identified to have close contact with
resorufin substrates, other key residues directly involved with the oxidation
phenacetin should be used alternatively as the reference points in the future to further
estimate the quality of the active site in our 2nd generation model.

Restrained Docking
As displayed in Figure 3.8, acetaminophen in both P450 1A1 and 1A2 models
adopted a similar orientation, while phenacetin occupied different conformations.
Since the enzyme-substrate complex models are optimized based on the NMR-derived
distance data on phenacetin-enzyme interaction, it is not surprising to see such a
difference with phenacetin.

While acetaminophen is the product of the oxidation of

phenacetin, a similar orientation assumed by docked acetaminophen indicates that
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Figure 3. 8. Models of phenacetin (yellow) and acetaminophen (green) bound in
the second generation of homology models of P450 1A1 and 1A2.
The most favorably ranked orientations for each docked substrate were refined by
restrained MD simulations to overlapping positions on the distal side of the heme
(red), adjacent to the I helix (cyan helix to the right).
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products like acetaminophen may leave the active site in a similar starting orientation
in both P450 1A1 and 1A2.
Another interesting finding is that all the orientations seem to be planar to the
heme plane, which is probably due to the distance restraints enforced during the
docking procedure, since these data exhibit very subtle differences among different
paired objects.

So far, we are not sure how these different docking results could

influence the catalytic activities regarding the oxidation of phenacetin.

More

experiments are required in order to further explain these phenomena.

Conclusions and Future Directions
We have successfully constructed a new generation of homology models of
P450s 1A1 and 1A2, which we created based on the structural information from
multiple crystal structures of eukaryotic P450s.

We have also incorporated NMR T1

relaxation-based distance restraints between the substrate and the heme iron to
optimize the active site. The resultant models exhibit a high quality of global folding
together with structural specifications. The high quality model should be able to
provide more accurate information to guide site-directed mutagenesis and better
explain structure-function relationships of P450 1As in the future.

Since the crystal

structure of P450 1A2 is currently available, restrained docking of phenacetin using
the same protocol as described above, will also be performed with this structure so
that we can further evaluate the applicability of our new generation of homology
models of P450 1As.

Moreover, the new model of P450 1A1 based on the structure

of P450 1A2 crystal will be constructed.
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Chapter 4

Asn-145→Lys Substitution in Human Cytochrome P450 1A2
Decreases Reductase Binding
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Abstract
Microsomal cytochromes P450 require cytochrome P450 reductase (CPR), for
catalysis. By modeling a P450-CPR complex, we have identified P450 1A1 surface
residues K143 and K456 corresponding to N145 and R457 of P450 1A2. In order to
further test the mutation’s effect on CPR binding and substrate specificity, we have
mutated Asn-145 of P450 1A2 to Lys.

The mutant enzyme displays a comparable

EROD/MROD ratio similar to that of P450 1A2 WT, which indicates that the mutant
exhibits similar substrate specificity and this substitution does not disrupt the
topology of the active site with respect to resorufin oxidation upon CPR binding.
However, the estimated affinity of the P450 1A2 N145K mutant for CPR was much
lower than that in the case of WT, as measured by NADPH oxidation rate. This
provides further support for the importance of this residue for CPR binding, and is
consistent with molecular modeling results.

106

Introduction
Cytochromes P450 (P450s) constitute a large family of enzymes ubiquitous in
living organisms.

They are versatile catalysts that can oxidize a vast variety of both

xenobiotic and endogenous compounds.

Due to their importance in drug metabolism,

the elucidation of their structure-function relationships is central to laying a
cornerstone for designing successful prediction methods which could provide insights
into the disposition of potential drug molecules even before administration [1].
Human P450 1A1 and 1A2 are two major isoforms in the P450 1A subfamily.
Although these two enzymes share 72% sequence identity [2], they still display
different substrate specificity.

Some substrates are metabolized by both enzymes,

but with different catalytic activities. Liu et al. (2004) have identified five key
residues that affect P450 1A1 and 1A2 specificities with substrates 7-ethoxyresorufin
(ERES) and 7-methoxyresorufin (MRES).

In particular, the substitution of Val-382

with Leu in P450 1A2 has significantly shifted substrate specificity towards that of
P450 1A1 [1, 2]. However, further modeling studies have suggested that even
simultaneous multiple substitutions at all five positions are not sufficient to switch the
specificity from one enzyme onto the other [unpublished data].

This further supports

the view that key residues responsible for the determination of specificity may not
only be limited to the active site. For example, residues in other functional domains,
such as ligand access pathway, CPR binding site, or even membrane anchoring region,
may also affect enzyme specificities, possibly through changes in enzyme
conformation.

Therefore, it is critical to take these residues into consideration to

comprehensively understand the structure-function relationship of P450 enzymes.
All class II P450 enzymes require a redox partner, cytochrome P450 reductase
(CPR), which provides electrons to support P450 catalysis. Like the P450 enzymes,

107

CPR is also a membrane-anchored protein. It contains two major domains, the FMN
domain and FAD domain [3].

So far, the arrangement of the P450-CPR complex has

not been determined by current techniques. Therefore, the combination of molecular
modeling and site-directed mutagenesis methods has been widely applied to identify
residues comprising the CPR binding region in several eukaryotic class II P450s [4, 5].
By and large the association of P450s and CPR is regarded to be governed by both
hydrophobic and electrostatic interactions, which may involve charge-pairing, as in
P450 2B4, but the strength of the association varies depending upon the type of P450
under study [5].

The determination of the crystal structures of several mammalian

P450s provides further details concerning the topography of the postulated
CPR-binding region [6].

Although the crystal structure of a mammalian CPR has

been solved [7, 8], its conformation appears to be inappropriate for binding of P450s.
A rather dramatic conformational shift is required to reorient the FMN domain so as
to effectively position it in proximity of the P450 heme [3].

In this way, the FMN

domain is assumed to provide a major surface for docking P450s.
It is still a puzzle whether CPR binding may induce conformational changes in
the P450.

Some conflicting results have been reported on that subject, which has led

to a prolonged debate on the issue [9-11].

According to some findings,

substrate-promoted allosteric regulation of CPR binding seems to play a major role in
optimizing electron flow to the heme prosthetic group.

This may occur by triggering

conformational changes upon ligand binding, as indicated by the study of P450
2B4-catalyzed reactions [4, 12].
In our present studies, we have identified key residues of P450 1A2 involved in
CPR binding using protein docking methods.
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We then created P450 mutants and

examined their activities to test whether the mutation in this region can affect CPR
binding and substrate oxidation.

Materials and Methods
Construction of the P450 1A2 N145K Mutant
QuickChange II kit was purchased from Stratagene ( La Jolla, CA) to carry out
site directed mutagenesis.

The pCWori+ plasmid containing the WT His-tag

P4501A2 cDNA served as a template [1].

The complementary primers (5’

CTGGCCCAGAATGCCCTC AACACCTTCTCCATCGCCTCT 3’) were used for
constructing the P450 1A2 N145K mutant. Additionally, 4% DMSO was added to
the polymerase chain reaction system.

The PCR conditions were adjusted as follows:

95°C for 1 minute for 1 cycle (pre-denature) followed by 95°C for 1 minute
(denature), 55°C for 1 minute (annealing) and 68°C for 15 minutes (elongation), for a
total of 12 cycles.

DNA sequencing was performed by Northwoods DNA , Inc.,

using the primer (5’-AGTTTTTCTGTTCTGCCTGG-3’).

All primers are ordered

from Sigma Genosys (St. Louis, MO) and all the other materials involved were
exactly as described in the previous work [1].

P450 Expression, Purification and Activity Assay
The wild type and mutant P450 1A2 enzymes, including the N145K mutant,
were expressed in E. coli and purified as described earlier [1, 2].

Rat P450 reductase

was expressed and purified using an earlier established protocol [1, 2].

7-Methoxy-

and 7-ethoxyresorufin O-dealkylase activities (MROD and EROD, respectively) of
P450 1A1 WT, 1A2 WT and mutants were assayed by flouorometric detection of
resorufin [1], using excitation and emission wavelengths of 550 and 585 nm,
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respectively. The reaction mixture, in a total volume of 250 µl, contained 50 nM
P450, 100 nM CPR, and 10 mM substrate in 100 mM phosphate buffer, pH 7.5.
Reactions were initiated by the addition of 10 µl of 100 mM NADPH.

For kinetic

assays, substrate concentration varied from 0.01 to 20 µM. For CPR binding studies,
the ratio of CPR to P450 ranged from 1:8 to 2:1

NADPH oxidation assay
The NADPH oxidation reaction was performed in a spectrophotometric cuvette at
37 oC.

Purified P450 enzymes and various concentrations of CPR ranging from 0 to

2 fold the amount of P450 were preincubated for 3 min at 37 oC in the presence of
substrate. Reactions were initiated by the addition of 50 µl of 4.0 mM NADPH and
mixing by inverting the cuvette several times, and the rate of absorbance decrease at
340 nm was immediately monitored continuously over the duration of 1 minute
(Beckman DU-640 spectrophotometer).

Rates of NADPH oxidation were calculated

using ε340 = 6.22 mM-1 cm-1 for NADPH.

All assays were performed in duplicate.

Kinetic

by

parameters

were

determined

nonlinear

fitting

method

using

Michaelis-Menten equation in the GraphPad Prism software [San Diego, CA].

Initial P450-CPR Docking
For docking experiments, we chose only the FMN domain of CPR, since it is the
most likely part of the enzyme that binds to a P450.

Initially, the x-ray structure of

the FMN-binding domain of human CPR (pdb code: 1blc) [3] and a previously
constructed homology model of P450 1A1 [13] were used as input structures for the
program GRAMM v1.03 [14, 15], run in a default mode and at low resolution with
the grid step of 6.8 Å. The results were displayed and analyzed with InsightII
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(Accelrys, San Diego). Additionally, we used the structure of P450 BM-3 complex
between the heme and FMN-binding domains (pdb code: 1bvy) [16], and
superimposed the structures of P450 1A1 and the FMN domain of CPR on their
equivalents in the BM-3 complex.

Interestingly, the results were virtually the same

as from docking using GRAMM. Potential CPR binding residues of P450 1A1
together with their putative interacting residues on the CPR surface have been
identified based on their spatial proximity in our model of the complex.

Equivalent

residues in P450 1A2 were determined from the sequence alignment with 1A1 [1].

Modeling of the P450-CPR Complex Using the Crystal Structure of P450 1A2
P450 1A1 homology model in the initial P450-CPR complex was replaced with
the crystal structure of P450 1A2 (pdb code: 2hi4) [19] by superimposing their
backbones. The cofactor FMN was constructed in Builder module of Insight II and
assigned partial charges automatically. The P450-CPR complex was subjected to
1000 iterations of energy minimization using the steepest descent. The P450 1A2
N145K mutant was generated by the replacement of Asn-145 with Lys followed by a
manual search from the rotamer library to choose the best energy favorable
conformation of the Lys side chain.

The complexes with either wild type P450 1A2

or the mutant N145K were further subjected to another round of 1000 iterations of
energy minimization, with protein-protein interaction energies sampled.

Results and Discussion
Identification of P450 Residues Involved in CPR Binding
GRAMM implements a pattern recognition algorithm to exhaustively search the
complementary geometric surfaces of the macromolecules. Although it is a fast
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method, its accuracy is still strongly limited by the enormous freedom of each residue
in the protein and the resolution of the target molecule. Nevertheless, it is widely
used as the preliminary protein docking tool to create the gross features as the starting
point of the protein complex, to be followed by minimization or simulations with
full-atom potentials [15].
However, in the case of docking of P450 1A1 and the CPR FMN domain, among
ten final results for the complex, eight of them have had the FMN domain consistently
placed in the proximal region of P450 1A1. This sends a strong sign that P450 1A1
and the CPR FMN domain are highly complementary in geometric surface and the
proximal regions may be the universal interface for redox partners such as CPR or
cytochrome b5, as suggested by earlier studies [4, 5].
Eleven residues of P450 1A1/1A2 have been identified as those likely involved
in CPR binding (Table 4.1). The residues in the corresponding positions in P450
1A2 have been selected based on the pairwise sequence alignment with P450 1A2.
Interestingly, only two out of eleven CPR bindings residues have different types of
amino acids at the corresponding positions in the two enzymes, of which apparently
Lys-456 (P450 1A1) is still a functionally conservative substitution for Arg-457 (P450
1A2), while the discrepancy between Asn-145 (P450 1A2) and Lys-143 (P450 1A1)
clearly merits more attention and exploration.
Since P450 BM3 is a fusion protein of P450 and CPR, it is often regarded as the
best prototype for the P450-CPR complex [16].

In order to discover the most

appropriate orientation for the CPR FMN domain in the complex from the cluster
produced by GRAMM, we also carried out a manual docking of P450 1A1 homology
model and CPR FMN domain by overlaying them with the heme domain and FMN
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Table 4.1. Surface residues of P450 1A2 which may have potential electrostatic or
hydrophobic interactions with the residues of CPR.
1. Electrostatic interactions
P450 1A2 residue: R95

R100a

CPR counterpart:

D91, E55

D87

N145b

K442

K455

D41

D148

E53, E56

2. Hydrophobic interactions
P450 1A2 residue:

A134

F147, W466

CPR counterpart:

M50

F156, I157, F34

I149,
W164,

a

The results were obtained using GRAMM.
K143 in equivalent position of P450 1A1
c
K456 in equivalent position of P450 1A1
b
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A150
F156

R457c
E32

domain from the same P450 BM3 structure, respectively.

The best matched

structure has been chosen as the model of the complex for further modeling.
Potential interacting residues residing on the surface of CPR have been also identified
from this model based on geometric proximity.

Conformational Changes Upon CPR Binding
EROD/MROD ratio, which was used as the specificity indicator, was maintained
at the same level in the P450 1A2 N145K mutant (0.397) as in the 1A2 WT enzyme
(0.390) and the 1A2 V227G mutant (0.365), in contrast to P450 1A1 WT (6.186) and
the 1A2 L382V mutant (2.057) (Table 4.2). Since the Leu-382→Val substitution in
P450 1A2 has been already proved to change the topology of the active site through
the effect on oxidation of resorufin substrates, the current result clearly indicates that
the replacement of Asn-145 with Lys could not affect the topology of the active site
regarding the specificity of resorufin substrates even upon CPR binding. Although
there is some variation in the values of Vmax, the EROD/MROD ratio of the P450 1A2
N145K mutants has been constant even when O-dealkylase activities were tested
under various concentrations of CPR (data not shown). In conclusion, our data
indicate that the N145K mutation in the CPR binding region of P450 1A2 does not
affect the topology of the active site regarding the specificity of oxidation of
alkoxyresorufin substrates. Thus, probable conformational changes at the P450-CPR
interface in the mutant that occur upon CPR binding should not affect the topology of
the active site which would influence alkoxyresorufin specificity.

Binding Affinity of CPR for P450s
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Table 4.2. Alkoxyresorufin O-dealkylase activities of P450 1A2 WT and mutants,
and P450 1A1 WT.
P450

%WT of 1A2 Activity

EROD/MROD

ERODa

MRODb

EROD

MROD

1A2WT

0.278c

0.713

100

100

0.390

1A2V227G

0.057

0.156

20.5

21.9

0.365

1A2N145K

0.181

0.456

65.1

64.0

0.397

1A2L382V

0.434

0.211

156

29.6

2.057

1A1WT

0.365

0.059

131

8.3

6.186

a

7-Methoxyresorufin O-demethylase activity.
7-Ethoxyresorufin O-deethylase activity.
c
O-Dealkylase activity as nmol product min-1 nmol P450-1.
b
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Table 4.3. Dissociation constants (KD) for binding of CPR to P450 1A2 WT, three
1A2 mutants and P450 1A1 WT.
P450 1A2

ERES

MRES

ERES/MRES

Kda

Kd

Kd

1A2WT

2.183

1.352

1.61

1A2V227G

2.415

1.558

1.55

1A2N145K

1.549

0.867

1.79

1A2L382V

0.373

0.577

0.65

1A1WT

1.424

1.284

1.11

The constants were estimated from O-dealkylase activity.
a
As the ratio of CPR vs. P450 (50 nM)
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Table 4.3 shows dissociation constants for binding of CPR to P450 1A2 WT
and mutants.

The KD values here were equal to Km for CPR, an approximation

which has been frequently used in these types of studies [20]. However, one must
keep in mind that the catalytic activity reflects a sum of various events including the
electron transfer, substrate binding and even product release.

In other words,

catalytic activity (Vmax) should not be regarded as the accurate estimation of the
amount of active P450-CPR complexes formed.

Furthermore, the extremely low KD

value in the case of P450 1A2 L382V also further complicates the interpretation of
CPR binding affinity for P450s, since the location of this mutation is deep in the
active site and thus unlikely to have contact with CPR.

It is still possible that this

mutation could induce conformational changes favorable for CPR binding as observed
for the A264E mutation in P450 BM3 [21], but obviously there is no evidence
supporting this idea so far.

On the other hand, the kinetic characteristics of the P450

1A2 N145K mutant as estimated by NADPH oxidation were totally different from
those of other active site mutants (Figure 4.1).

Moreover, the binding affinity for

CPR as estimated by NADPH oxidation (Table 4.4) has also been greatly decreased in
P450 1A2 N145K compared to KDs of active site mutants and P450 1A2 WT.

This

may indicate that the NADPH oxidation rate is actually superior than O-dealkylation
activity in estimating the apparent dissociation constant for CPR binding to P450s,
although it is still not the reflection of the pure binding process [22].

Further Molecular Modeling Validation
The calculated intermolecular interaction energy of wild type P450 1A2 and the
CPR-FMN domain is around -1595.7 kcal/mol, just slightly higher than that of the
complex containing P450 1A2 N145K and CPR-FMN (-1599.9 kcal/mol).
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Figure 4.1. Rate of NADPH consumption by P450 1A2 wild type, three mutants
and 1A2 wild type as a function of the ratio of CPR vs. P450.
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Table 4.4. Dissociation constant (KD) for the binding of CPR to P450 1A2 WT,
three mutants and P450 1A1 WT.
P450 1A2

ERES

MRES

KDa

KD

1A2WT

0.144

0.238

1A2V227G

0.164

0.317

1A2N145K

2.091

1.432

1A2L382V

0.149

0.320

1A1WT

0.233

0.281

KD was estimated by NADPH oxidation.
a
As the ratio of CPR vs. P450 (50 nM)
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Table 4.5. Energy contributions table
P450 1A2

Residue in
P4501A2

Residue in
CPR-FMN

VDW

Electrostatic

Total Energy

Wild Type

Asn-145

Lys-40

-0.51484

-8.68852

-9.20336

Asp-41

-0.06795

-1.39627

-1.46421

Lys-40

-1.77537

4.39512

2.61975

Asp-41

-0.84343

-3.21859

-4.06202

N145K

Lys-145

Energy contributions including Electrostatic, Van der Waals and Total [kcal/mol] to
the interactions between residues of P450 1A2 and the interacting residues in
CPR-FMN domain were calculated by Discover.
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Considering the size of the molecules involved, there should not be any
difference regarding their CPR binding capability. However, if we focus only on the
specific residues, as shown in Table 4.5, the interaction energy between Lys-145 of
P4501A2 and its counterpart, Lys-40 in the CPR-FMN domain, for the complex
formed by P4501A2 N145K and CPR-FMN domain is significantly greater (2.61975)
than that in the complex of P450 1A2 WT and CPR (-9.20336).

This indicates that

the Asn-145→Lys mutation in P450 1A2 leads to a less favorable complex compared
with the wild type.

At the same time, the interaction energy between Lys-145 in the

P4501A2 N145K mutant and Asp-41 in CPR-FMN domain is decreased (from
-1.4621 to -4.06202), likely due to the formation of a new salt bridge (See Figure 4.2).
However, it seems that this bridge is not sufficient to compensate for the increased
interaction energy between Lys-145 and Lys-40 of CPR, as compared to that observed
for Asn-145 of 1A2 WT.
This result suggests that the binding affinity of CPR to P450 is in fact determined
by the complementarity of topology, specifically by the hydrophobic patches instead
of charged pairs.

On the other hand, the enhanced electrostatic interactions,

especially between oppositely charged residue pairs from the interacting molecules
could still significantly increase the electron transfer rate from CPR to P450 enzymes
by possibly activating some new electron transfer pathways. This could explain that
in the case of the mutant P450 1A2 N145K, Vmax for NADPH oxidation is greatly
increased, while the binding affinity decreases, as indicated by increased KD for CPR.
Actually, the initial idea for this project was to increase the P450-CPR binding
affinity by introducing more charged pairs between these two molecules by
introducing Lys-145 to replace Asn-145 in P450 1A2 to be coupled with Asp-40.
However, the results suggest that the binding affinity of CPR to P450 is determined
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Figure 4.2. Comparison of the interactions between P450 1A2 and CPR
regarding the mutation N145K.
Comparison of N145 in 1A2 wild type and K145 in 1A2 N145K have been depicted
(small snapshot only focused on the involved residues). The backbone of P450 and
CPR are depicted as pink and green respectively with heme and FMN cofactors both
in brown. N145/K145 is colored yellow, K41 in blue and D40 in red.
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by the complementarity of topology, specifically by the hydrophobic patches instead
of charged pairs.

Electrostatic interactions play an important role in orienting the

proteins for productive collisions required for initial electron transfer complex
formation [4], but these interactions are not absolutely necessary for the ultimate
arrangement for electron transfer [24]. On the contrary, charge repulsion between
negatively charged residues on a P450 enzyme and the CPR-FMN domain could
disrupt the formation of the complex [25].

This strongly suggests that

complementary hydrophobic interactions may dominate as the principal driving force
for binding, the enhanced electrostatic interactions, especially between oppositely
charged residue pairs from the interacting molecules, could still substantially increase
the electron transfer rate from CPR-FMN domain to P450 enzymes by possibly
activating new electron transfer pathways.

This could explain the fact that in the

case of the P450 1A2 N145K mutant, Vmax for NADPH oxidation greatly increased,
while the binding affinity decreased, as indicated by increased KD for CPR.
Taken together, EROD/MROD successfully operates as a topology probe
regarding the oxidation of alkoxyresorufin substrates.

The ratio of these catalytic

rates is used to quantify, indirectly, the changes in the active site topology which
profoundly alter alkoxyresorufin specificity. This descriptive ratio can be directly
correlated with the conformational changes induced by CPR binding, mutations or
any other types of perturbations in P450s.

In the case of the P4501A2 N145K

mutant, the interference introduced by this mutation on the CPR binding could not
affect the topology of the active site, as suggested by the EROD/MROD ratio similar
to that of P450 1A2 wild type.

This could be regarded as a sign that CPR binding

will not induce the conformational changes in the active site regarding the oxidation
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of resorufin substrates, even though more comprehensive experiments such as binding
different types of mutated CPRs are required to verify this idea.
Moreover, the controversy about the binding affinity estimation by substrate
oxidation and NADPH oxidation rate leads to a long lasting dilemma for the study of
P450 CPR interactions, since as yet no advanced techniques could detect the binding
affinity directly and precisely.

Both measurements are only representatives of

multiple processes instead of the pure complex formation between P450 and CPR, and
the measurements could not be the true KD values as expected.

Considering all the

complications discussed above, the distinctively abnormal behavior in kinetics of
NADPH oxidation rate for P450 1A2 N14K still strongly distinguishes it from other
mutants and possibly implies that this mutation weakens CPR binding affinity instead
of substrate oxidation or electron transfer efficiency, which can be further clarified by
the energy contributions by the individual residue involved in our molecular modeling
analysis. Certainly, further studies should verify how and when the rate of formation
of the active P450-CPR component is proportional to the consumption rate of
NADPH in order to validate the assumption.
Only energy minimization was applied to evaluate the feasibility of mutations
of P450 for CPR binding since we wanted to avoid dissociation of the complex that
could occur during molecular dynamics simulation.

More innovative ideas have to

be introduced to further update the modeling part of the complex so as to resolve the
complexities around CPR binding and electrons transfer processes.
Finally, both the quality of the homology model of P450 1A2 we constructed
before and protein docking protocol have been validated and shown to be useful.
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Conclusions and Future Directions
P450-CPR complex model has been successfully applied to identity key residues
on the CPR binding surface of P450 1As and explain the effects of mutations.

The

Asn-145→Lys mutation in P450 1A2 has been shown not to affect substrate
specificity, thus most probably resides on the surface interacting with CPR.

Enzyme

kinetics study indicated that the estimated binding affinity of the P450 1A2 N145K
mutant for CPR was much lower than in the case of WT.

Advanced computational

methods will be applied to further optimize the interface topology of the P450-CPR
complex and to evaluate the binding free energy of CPR-FMN domain to P450 1A2
wild type and the mutant N145K.
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Chapter 5

Large Scale MD Simulations of P450 1A2 in Explicit Membrane:
Comparison of Two Possible Anchoring Orientations
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Abstract
Human cytochrome P450 1A2 is one of the major P450 enzymes responsible for
metabolizing miscellaneous drugs. Because most eukaryotic P450s are located in
the endoplasmic reticulum and intrinsically associated with the membrane, their
orientation in the membrane may affect substrate specificity.

Since, based on

available data, at least two possible modes of P450 1A2-membrane association are
possible, we propose to determine which type of P450 anchoring is more likely to
occur.

The P450-membrane complexes were constructed by insertion of the protein

into the explicit POPC (Palmitoyl Oleoyl Phosphatidyl Choline) membrane and
optimization of the system using minimization and 50 ps of molecular dynamics.
Presently, we plan to subject this system (two alternative complexes) to longer MD
equilibration (500 ps) and to 10 ns productive MD simulations.

Various parameters

such as system stability, ligand access pathway and the feasibility of binding the
reductase partner, CPR, to the P450, will be systematically analyzed and compared in
order to choose the more plausible mode.
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Introduction
Cytochromes P450 constitute a large family of enzymes that exist in a wide
variety of living organisms and oxidize xenobiotic and endogeneous compounds.
Cytochrome P450 1A2 is a class II isoform commonly found in human beings that
operates as one of the major drug-metabolizing P450 enzymes [1].

The

structure-function relationships with respect to substrate specificity and ligand
selection has been widely studied [2-3], however, the results suggested that key
residues in the active site and structural recognition sites (SRSs) are not sufficient to
explain the complexity of the reaction.

Possibilities have been considered for

residues in other functional domains such as CPR binding and membrane anchoring
sites.

These residues may not have a direct contact with the ligand, but could still

affect the reaction, probably by affecting events such as electron transfer, substrate
entrance or product release.
Class II P450s differ from class I P450s in that the former enzymes are tightly
anchored with ER membranes.
unknown [4].

However, the exact details of this association are still

Many attempts to make P450 2Cs soluble in order to meet the

requirement of crystallization have strongly indicated that F, G helices and/or F-G
loop could also be involved with this association, besides the uniformly agreed on the
N-terminal trans-membrane helix [5]. This supposition has been confirmed by
successfully creating several highly soluble P450 2C5 forms through introducing
more mutations in the F-G loop [6].
Considering that both P450 and CPR need the membrane as the necessary
environment, it is reasonable to propose that how this association is orientated within
the membrane will have some influence on ligand selection or probably even other
characteristics of P450 catalysis.

Since this association architecture will also

131

subsequently affect the orientation and location of the ligand access pathways, these
membrane association studies will facilitate detailed analysis of the ligand access
pathways. Although in the past few years various computational methods have been
applied in discovering these pathways, none of them has ever considered the effect of
the membrane [7, 8], which may alter the conclusions.
Recently, simulations of proteins with explicit membrane have been widely
applied in the exploration of the association of proteins with their partner membrane
segments in many fields [9, 10].

Although the analysis techniques are still not

mature, these advanced methods shed some light on the possibility of theoretically
studying the complicated protein-membrane interactions.
In our present study, we intended to set up the P450 1A2-membrane system and
to construct two possible association modes with the respect of the relative angle of
heme plane of the P450 to the membrane normal.

Long-period intensive molecular

dynamic simulations are expected to discover which model is more plausible as
judged by its stability.

Modeling Methods
System Construction
Residues from 34 to 513 of the crystal structure of cytochrome P450 1A2 (pdb
code: 2hi4) [11] were used to create the P450-membrane association.
was applied to construct the whole system.

VMD1.8.6 [12]

Firstly, we constructed a POPC

membrane with the surface of 90 Å x 90 Å. Then we manually inserted the putative
transmembrane part of the P450 into the membrane in either of two ways: 1) with
heme plane vertical to the normal of the membrane (V mode) and 2) with heme plane
parallel to the normal of the membrane (P model).
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In both modes, only residues in F,

G helices the F-G loop could be submerged into the membrane.

Modified tk/tcl

scripts were developed to remove lipid molecules stacked with the protein, followed
by the solvation of the whole system in water again.

Finally, counter-ions were

added to balance the charge using the addion plugin in VMD.

CHARMM27 force

field with the modified topology and parameters for cysteine-linked heme was used
for the whole system.

System Refinement
We used NAMD2.6b1, a parallel classical molecular dynamics algorithm to
minimize and equilibrate our system [14].

Firstly, 2000 iterations of minimization

were employed followed by molecular dynamics simulations with the backbone atoms
of the protein restrained using a constant of 10 kcal/mol for 20 ps. Then the whole
system was subject to another 200 ps MD equilibration so as to make the whole
system ready to perform long term production MD simulation.

Preliminary Results and Discussion
Study of hydrophobic patches of P450 1A2 and 2B4 [13] indicated that besides
the N- terminal trans-membrane domain, which is inserted in and spans the membrane,
there are still some other regions, such as F and G loop, or even the region near the B
and C loop, that may be at least partially immersed in the membrane (Figure 5.1).
This information will help us to properly insert P450 1A2 into the membrane lipid.
The whole system in V model includes 69667 atoms and P model has 73124 atoms
(Figure 5.3). The protein-membrane system was successfully set up (Figure 5.2) and
is ready for further simulations.
This is the first time a P450 enzyme was simulated with explicit membrane
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environment.

It is expected that it will give some instructive information on ligand

entrance, CPR binding and P450 oligomerization.

Conclusions and Future Directions
Construction and preliminary simulations on P450 1A2 with explicit membrane
have been performed.

Two distinct association modes of P450 1A2 with the explicit

membrane are proposed. Further study will implement intensive MD simulations on
these systems and various parameters such as system stability, ligand access pathway
and the feasibility of binding the reductase partner, CPR, to the P450, will be
systematically analyzed and compared in order to choose the most plausible mode.
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(A)
Figure 5.1.

P450 1A2

(B) P450 2C5

The solvent-accessible surface of P450 1A2 and 2B4.

The solvent-accessible surface of P450 1A2 (A) and P450 2B4-bifonazole complex (B)
are shown in the putative membrane-binding orientation. The surface is colored
according to the property of the underlined residues: yellow indicates hydrophobic
residues (Ala, Gly, Ile, Leu, Met, Pro, Val, Phe, Tyr, and Trp-10); white indicates polar
residues (His, Asn, Gln, Ser, Thr, and Cys:6); red indicates negatively charged
residues (Asp and Glu); and blue indicates positively charged residues(Lys and Arg).
(A) is drawn in InsightII, (B) is adapted from Zhao et al. 2006 [13].
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Figure 5.2.

P450 1A2 in a fully hydrated membrane.
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(A)

(B)

Figure 5.3. Two association orientations of P450 1A2 within POPC membrane
(A) Vertical model

(B) Parallel model
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Chapter 6

Summary and Conclusions
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We have investigated various functional domains of P450 1As to explore their
structure-function relationships. Molecular modeling methods including homology
modeling, ligand docking, protein docking, and molecular dynamics have been
integrated with experimental techniques such as site-directed mutagenesis and kinetic
assays.
In chapter 2, we examined the ligand binding site of P450 1A2 by extensively
exploring the role of the five key residues identified in our previous studies. The
objective of this study was to investigate whether any multiple amino acid
substitutions in P450 1A2 may result in shifting the substrate specificity of the
mutants to that of P450 1A1. A total of 26 multiple mutants, varying from double to
quintuple and representing all possible residue combinations, were evaluated using
molecular modeling.

Thus, instead of exhaustively preparing all the twenty six

multiple mutants in vitro, we first developed an in silico prediction model by
correlating the in silico MD-based descriptors with the experimental specificities of
P450 1A2 WT and its single mutants.

This model was then utilized to help screen

the multiple mutant candidates with the potential specificity shift towards that of P450
1A1.

Seven out of twenty six multiple mutants have been selected and five of them

have been further examined by the combination of site-directed mutagenesis and
functional assays.

Interestingly, against our initial expectations, the simultaneous

substitutions of all five key residues could not entirely interconvert the specificity
towards that of P450 1A1.

This gave a strong indication that other functional

domains besides the ligand binding site could also be involved with the specificity
determination.
Therefore, in chapter 4, we extended our studies into the reductase binding site of
P450s. The protocol employed for identifying key residues in the active site has been
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also applied here to discern the key residues at the CPR binding site, except that
protein-protein docking methods have been utilized instead of protein-ligand docking.
A combination of site-directed mutagenesis and various functional studies has shown
that the substitution of Asn-145 of P450 1A2 to Lys did not disrupt the topology of the
active site, since there was no effect on oxidation of resorufin substrates upon
reductase binding.

However, this mutation has decreased reductase binding based on

the NADPH consumption rate.
In chapter 5, we have initiated novel preliminary studies into P450-membrane
interactions by proposing two anchoring orientations for P450 1A2 in the ER
membrane.

The whole system has been constructed by submerging the crystal

structure of P450 1A2 into the explicit POPC membrane in two different modes.
The complex has been subjected to energy minimization in order to equilibrate the
whole system and prepare it for the coming productive MD stages. The intensive
molecular dynamics simulation is expected to be able to provide adequate information
for evaluating the feasibility of the membrane association model of P450 1A2.
Since most of the work has been initialized and even completed before the
appearance of the crystal structure of P450 1A2 in 2007, homology models of P450
1As have been widely used throughout these projects.

However, even small

structural deviations of the homology model from the real structure may lead to huge
differences regarding various types of modeling predictions.

Consequently,

homology models need to be updated whenever any new resources are available.
Therefore, in chapter 3, we described the detailed process of constructing a
second-generation of homology models based on nine crystal structures from class II
P450s and used distance restraints from T1 NMR relaxation experiments.

Compared

with the old models that used only the structure of P450 2C5 as a template, these
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updated models have been found to have less structural violations and were able to
accommodate phenacetin- like ligands.
Generally, in this research, we intended to utilize diverse molecular modeling
techniques to study various functional domains of P450 1As.

This research helped

us to elucidate a structural basis of enzyme activity and give insight into the
underlying mechanisms of several events, such as specificity determination, reductase
binding and membrane anchoring. Our results strongly indicate that P450-catalyzed
system is highly coordinated and adaptable, and it is advisable to take all the
functional domains into consideration when studying the structure-function
relationship of these enzymes.
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